CN116514779A - 2,4-二取代-5-氟嘧啶衍生物及其制备方法和应用 - Google Patents
2,4-二取代-5-氟嘧啶衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN116514779A CN116514779A CN202310456800.3A CN202310456800A CN116514779A CN 116514779 A CN116514779 A CN 116514779A CN 202310456800 A CN202310456800 A CN 202310456800A CN 116514779 A CN116514779 A CN 116514779A
- Authority
- CN
- China
- Prior art keywords
- amino
- phenyl
- benzo
- compound
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 2, 4-disubstituted-5-fluoropyrimidine Chemical class 0.000 title claims abstract description 180
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 150000001875 compounds Chemical class 0.000 claims abstract description 177
- 206010023421 Kidney fibrosis Diseases 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims description 71
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 55
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 claims description 21
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 13
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 9
- 206010016654 Fibrosis Diseases 0.000 claims description 9
- 230000004761 fibrosis Effects 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical compound C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 claims description 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 8
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000001589 carboacyl group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000005189 alkyl hydroxy group Chemical group 0.000 claims description 3
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- SANOUVWGPVYVAV-UHFFFAOYSA-N isovaleramide Chemical group CC(C)CC(N)=O SANOUVWGPVYVAV-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical group CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical group CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical group CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 104
- 239000007787 solid Substances 0.000 description 82
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 62
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- 238000006243 chemical reaction Methods 0.000 description 30
- 239000002904 solvent Substances 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 102100032827 Homeodomain-interacting protein kinase 2 Human genes 0.000 description 23
- 101001066401 Homo sapiens Homeodomain-interacting protein kinase 2 Proteins 0.000 description 23
- 239000000843 powder Substances 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000010410 layer Substances 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 18
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 17
- 229940127204 compound 29 Drugs 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 16
- 229940125833 compound 23 Drugs 0.000 description 16
- 229940125846 compound 25 Drugs 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- 239000003054 catalyst Substances 0.000 description 15
- 210000003734 kidney Anatomy 0.000 description 15
- 238000001035 drying Methods 0.000 description 14
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 14
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 11
- FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 10
- 239000002033 PVDF binder Substances 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 229940126208 compound 22 Drugs 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000007789 sealing Methods 0.000 description 9
- 238000000967 suction filtration Methods 0.000 description 9
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 210000005084 renal tissue Anatomy 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- YGHRJJRRZDOVPD-UHFFFAOYSA-N 3-methylbutanal Chemical compound CC(C)CC=O YGHRJJRRZDOVPD-UHFFFAOYSA-N 0.000 description 7
- 239000007810 chemical reaction solvent Substances 0.000 description 7
- 230000008021 deposition Effects 0.000 description 7
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 6
- 229940125961 compound 24 Drugs 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000003292 glue Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 206010003694 Atrophy Diseases 0.000 description 5
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 230000037444 atrophy Effects 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 210000000626 ureter Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 4
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 4
- 229940126657 Compound 17 Drugs 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000010339 dilation Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- OKRROXQXGNEUSS-UHFFFAOYSA-N 1h-imidazol-1-ium-1-carboxylate Chemical compound OC(=O)N1C=CN=C1 OKRROXQXGNEUSS-UHFFFAOYSA-N 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 3
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000002300 anti-fibrosis Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940125851 compound 27 Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- BSGIKRCNMBTGEB-UHFFFAOYSA-N (5-bromo-1-methylpyrrolo[2,3-c]pyridin-2-yl)-[6-[(dimethylamino)methyl]-4-methyl-3,4-dihydro-1h-isoquinolin-2-yl]methanone Chemical compound BrC1=NC=C2N(C)C(C(=O)N3CC(C4=CC(CN(C)C)=CC=C4C3)C)=CC2=C1 BSGIKRCNMBTGEB-UHFFFAOYSA-N 0.000 description 2
- YHUKWWWCNSTFHL-RIYZIHGNSA-N (5E)-5-[[6-oxo-5-(6-piperazin-1-ylpyridin-3-yl)-1H-pyridin-3-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound O=C1NC(=O)\C(S1)=C/c1c[nH]c(=O)c(c1)-c1ccc(nc1)N1CCNCC1 YHUKWWWCNSTFHL-RIYZIHGNSA-N 0.000 description 2
- VICOOSNNZUPVHM-IGPZRPDBSA-M (e,3r,5s)-7-[2-(4-fluorophenyl)-4-(3-phenylpentan-3-yl)phenyl]-3,5-dihydroxyhept-6-enoate Chemical compound C=1C=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=CC=1C(CC)(CC)C1=CC=CC=C1 VICOOSNNZUPVHM-IGPZRPDBSA-M 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- MXPCZHSTOIKVST-UHFFFAOYSA-N 1-[3-amino-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(2-hydroxyethoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=CC(N)=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OCCO)=C1 MXPCZHSTOIKVST-UHFFFAOYSA-N 0.000 description 2
- OXTVBHDILDPYAS-UHFFFAOYSA-N 1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(3-hydroxypropoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OCCCO)=C1 OXTVBHDILDPYAS-UHFFFAOYSA-N 0.000 description 2
- AXHVEQQLKVIZLO-UHFFFAOYSA-N 2-[4-[2-[5-(2,2-dimethylbutyl)-1h-imidazol-2-yl]ethyl]phenyl]benzoic acid Chemical compound CCC(C)(C)CC1=CNC(CCC=2C=CC(=CC=2)C=2C(=CC=CC=2)C(O)=O)=N1 AXHVEQQLKVIZLO-UHFFFAOYSA-N 0.000 description 2
- MGOLNIXAPIAKFM-UHFFFAOYSA-N 2-isocyanato-2-methylpropane Chemical compound CC(C)(C)N=C=O MGOLNIXAPIAKFM-UHFFFAOYSA-N 0.000 description 2
- BXVSAYBZSGIURM-UHFFFAOYSA-N 2-phenoxy-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide Chemical compound O1CC2=CC=CC=C2OP1(=O)OC1=CC=CC=C1 BXVSAYBZSGIURM-UHFFFAOYSA-N 0.000 description 2
- UIADWSXPNFQQCZ-UHFFFAOYSA-N 4-[4-(3,4-dichlorophenyl)-5-phenyl-1,3-oxazol-2-yl]butanoic acid Chemical compound ClC=1C=C(C=CC=1Cl)C=1N=C(OC=1C1=CC=CC=C1)CCCC(=O)O UIADWSXPNFQQCZ-UHFFFAOYSA-N 0.000 description 2
- MFLMXRSHJVIMRF-DHIUTWEWSA-L 4-[[[5-[(3r,5r)-6-carboxylato-3,5-dihydroxyhexyl]-1-ethyl-4-(4-fluorophenyl)-3-methylpyrrole-2-carbonyl]amino]methyl]benzoate Chemical compound CCN1C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=2C=CC(F)=CC=2)C(C)=C1C(=O)NCC1=CC=C(C([O-])=O)C=C1 MFLMXRSHJVIMRF-DHIUTWEWSA-L 0.000 description 2
- MVXAKOGJWVQPKC-UHFFFAOYSA-N 5-(3-ethynyl-5-fluorophenyl)-2-pyridin-2-yl-4,6,7,8-tetrahydro-[1,3]oxazolo[4,5-c]azepine Chemical compound FC1=CC(C#C)=CC(N2CC=3N=C(OC=3CCC2)C=2N=CC=CC=2)=C1 MVXAKOGJWVQPKC-UHFFFAOYSA-N 0.000 description 2
- NMXZFNZNFZYNMA-UHFFFAOYSA-N 7-[(2-chloro-6-fluorophenyl)methyl]-8-[2-(dimethylamino)ethylamino]-1,3-dimethylpurine-2,6-dione Chemical compound CN(C)CCNC1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CC1=C(F)C=CC=C1Cl NMXZFNZNFZYNMA-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N Cysteine Chemical compound SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 238000012313 Kruskal-Wallis test Methods 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 2
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- 235000002597 Solanum melongena Nutrition 0.000 description 2
- 244000061458 Solanum melongena Species 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 230000004156 Wnt signaling pathway Effects 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- LFUPTQIEOBBAJE-VIFPVBQESA-N gtpl6338 Chemical compound C([C@@H](O1)C)NC(C2=3)=C1C=NC=3SC(C1=O)=C2N=CN1C1=CC=C(Cl)C=C1 LFUPTQIEOBBAJE-VIFPVBQESA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 2
- 229960001920 niclosamide Drugs 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 2
- 229960003073 pirfenidone Drugs 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- JWUBVPJWWYYRLJ-UHFFFAOYSA-N tert-butyl 4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(B2OC(C)(C)C(C)(C)O2)C=N1 JWUBVPJWWYYRLJ-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- LAJAFFLJAJMYLK-CVOKMOJFSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[[(7s)-4-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5h-benzo[7]annulen-3-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N1([C@H]2CCC3=CC=C(C(=C3CC2)OC)NC=2N=C(C(=CN=2)Cl)N[C@H]2[C@H]([C@@]3([H])C[C@@]2(C=C3)[H])C(N)=O)CCOCC1 LAJAFFLJAJMYLK-CVOKMOJFSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- DIXMBHMNEHPFCX-MCMMXHMISA-N (2r)-2-[5-[6-amino-5-[(1r)-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]pyridin-3-yl]-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol Chemical compound O([C@H](C)C=1C(=CC=C(F)C=1)N1N=CC=N1)C(C(=NC=1)N)=CC=1C=1SC([C@](C)(O)CO)=NC=1C DIXMBHMNEHPFCX-MCMMXHMISA-N 0.000 description 1
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 1
- HPJGEESDHAUUQR-SKGSPYGFSA-N (2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(2s)-3-naphthalen-2-yl-2-(3-pyridin-3-ylpropanoylamino)propanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]buta Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)CCC=1C=NC=CC=1)CC1=CC=CC=C1 HPJGEESDHAUUQR-SKGSPYGFSA-N 0.000 description 1
- FOLCUFKJHSQMEL-BIXPGCQOSA-N (4-butylcyclohexyl) N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate Chemical compound CCCCC1CCC(CC1)OC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O FOLCUFKJHSQMEL-BIXPGCQOSA-N 0.000 description 1
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
- RXNPEQZHMGFNAY-GEALJGNFSA-N (5R)-4-[(1S,6R)-5-[(2S)-2-(4-chlorophenyl)-3-(propan-2-ylamino)propanoyl]-2,5-diazabicyclo[4.1.0]heptan-2-yl]-5-methyl-6,8-dihydro-5H-pyrido[2,3-d]pyrimidin-7-one Chemical compound C[C@@H]1CC(=O)NC2=C1C(=NC=N2)N3CCN([C@H]4[C@@H]3C4)C(=O)[C@H](CNC(C)C)C5=CC=C(C=C5)Cl RXNPEQZHMGFNAY-GEALJGNFSA-N 0.000 description 1
- UXKLQDCALAWFIU-VKNDCNMPSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-tetradecoxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCCCC)C1=CC=CC=C1 UXKLQDCALAWFIU-VKNDCNMPSA-N 0.000 description 1
- VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-M (S)-lactate Chemical compound C[C@H](O)C([O-])=O JVTAAEKCZFNVCJ-REOHCLBHSA-M 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- SGPLAXFUDTWHRS-UHFFFAOYSA-N 1-(4-nitrophenyl)piperidine Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1CCCCC1 SGPLAXFUDTWHRS-UHFFFAOYSA-N 0.000 description 1
- PWCFKNYSCGRNRW-UHFFFAOYSA-N 1-(4-nitrophenyl)pyrrole Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1C=CC=C1 PWCFKNYSCGRNRW-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- PWJNDVAKQLOWRZ-UHFFFAOYSA-N 1-hydroxynaphthalene-2-sulfonic acid Chemical compound C1=CC=C2C(O)=C(S(O)(=O)=O)C=CC2=C1 PWJNDVAKQLOWRZ-UHFFFAOYSA-N 0.000 description 1
- KYWMCFOWDYFYLV-UHFFFAOYSA-N 1h-imidazole-2-carboxylic acid Chemical class OC(=O)C1=NC=CN1 KYWMCFOWDYFYLV-UHFFFAOYSA-N 0.000 description 1
- BOMIIKYVZJCFQV-UHFFFAOYSA-N 1h-isoquinolin-2-amine Chemical compound C1=CC=C2C=CN(N)CC2=C1 BOMIIKYVZJCFQV-UHFFFAOYSA-N 0.000 description 1
- FJMQJSUOOGOWBD-UHFFFAOYSA-N 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-5,6-dihydropyrazolo[3,4-f][1,4]oxazepin-8-one Chemical compound O=C1N(CC(F)(F)C)CCOC=2C1=NN(C=1C(=CC=CC=1)Cl)C=2C1=CC=C(Cl)C=C1 FJMQJSUOOGOWBD-UHFFFAOYSA-N 0.000 description 1
- DWUJDNHHQKEOPR-UHFFFAOYSA-N 2-(2-piperidin-4-ylethyl)pyridine Chemical compound C1CNCCC1CCC1=CC=CC=N1 DWUJDNHHQKEOPR-UHFFFAOYSA-N 0.000 description 1
- UYJNQQDJUOUFQJ-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-4-(4-morpholinyl)anilino]-4-pyrimidinyl]amino]-N-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1Cl UYJNQQDJUOUFQJ-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- NLBSQHGCGGFVJW-UHFFFAOYSA-N 2-carboxyethylphosphonic acid Chemical compound OC(=O)CCP(O)(O)=O NLBSQHGCGGFVJW-UHFFFAOYSA-N 0.000 description 1
- LUILYCDVBBJPSJ-UHFFFAOYSA-N 2-chloro-5-fluoro-n-(4-morpholin-4-ylphenyl)pyrimidin-4-amine Chemical compound FC1=CN=C(Cl)N=C1NC1=CC=C(N2CCOCC2)C=C1 LUILYCDVBBJPSJ-UHFFFAOYSA-N 0.000 description 1
- RIOSJKSGNLGONI-UHFFFAOYSA-N 2-phenylbenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 RIOSJKSGNLGONI-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- GXRHHVJHXFTFJW-UHFFFAOYSA-N 2-tert-butyl-4-(4-nitrophenyl)piperazine-1-carboxylic acid Chemical compound C1CN(C(O)=O)C(C(C)(C)C)CN1C1=CC=C([N+]([O-])=O)C=C1 GXRHHVJHXFTFJW-UHFFFAOYSA-N 0.000 description 1
- BUTKIHRNYUEGKB-UHFFFAOYSA-N 3,3-dimethylbutanoyl chloride Chemical compound CC(C)(C)CC(Cl)=O BUTKIHRNYUEGKB-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-M 3-(N-morpholino)propanesulfonate Chemical compound [O-]S(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-M 0.000 description 1
- MWDVCHRYCKXEBY-LBPRGKRZSA-N 3-chloro-n-[2-oxo-2-[[(1s)-1-phenylethyl]amino]ethyl]benzamide Chemical compound N([C@@H](C)C=1C=CC=CC=1)C(=O)CNC(=O)C1=CC=CC(Cl)=C1 MWDVCHRYCKXEBY-LBPRGKRZSA-N 0.000 description 1
- IAJDSUYFELYZCS-UHFFFAOYSA-N 4-(4-nitrophenyl)morpholine Chemical compound C1=CC([N+](=O)[O-])=CC=C1N1CCOCC1 IAJDSUYFELYZCS-UHFFFAOYSA-N 0.000 description 1
- APSSAJKZELMQNM-UHFFFAOYSA-N 4-chloro-5-fluoropyrimidine Chemical compound FC1=CN=CN=C1Cl APSSAJKZELMQNM-UHFFFAOYSA-N 0.000 description 1
- PHNDZBFLOPIMSM-UHFFFAOYSA-N 4-morpholin-4-ylaniline Chemical compound C1=CC(N)=CC=C1N1CCOCC1 PHNDZBFLOPIMSM-UHFFFAOYSA-N 0.000 description 1
- RAUWPNXIALNKQM-UHFFFAOYSA-N 4-nitro-1,2-phenylenediamine Chemical compound NC1=CC=C([N+]([O-])=O)C=C1N RAUWPNXIALNKQM-UHFFFAOYSA-N 0.000 description 1
- GZCIRDMRXVOXPH-UHFFFAOYSA-N 4-nitro-n,n-dipropylaniline Chemical compound CCCN(CCC)C1=CC=C([N+]([O-])=O)C=C1 GZCIRDMRXVOXPH-UHFFFAOYSA-N 0.000 description 1
- URAARCWOADCWLA-UHFFFAOYSA-N 4-pyrrolidin-1-ylaniline Chemical compound C1=CC(N)=CC=C1N1CCCC1 URAARCWOADCWLA-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N 5-oxo-D-proline Chemical compound OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- XDBHURGONHZNJF-UHFFFAOYSA-N 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1C1=NC(C=2N=C(C=CC=2)C(O)=O)=CS1 XDBHURGONHZNJF-UHFFFAOYSA-N 0.000 description 1
- FCBOUJYKAGWYQM-DEOSSOPVSA-N 6-[[(2s)-1-hydroxy-3-phenylpropan-2-yl]amino]-n-(2-phenoxyethyl)-2-(3,4,5-trimethoxyphenyl)pyridine-3-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(C=2C(=CC=C(N[C@H](CO)CC=3C=CC=CC=3)N=2)C(=O)NCCOC=2C=CC=CC=2)=C1 FCBOUJYKAGWYQM-DEOSSOPVSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- LDIOUQIXNSSOGU-UHFFFAOYSA-N 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5h-cyclopenta[d]pyrazolo[1,5-a]pyrimidine Chemical compound CC1=NN2C(NC(CC)CC)=C3CCCC3=NC2=C1C1=CC=C(OC)C=C1Cl LDIOUQIXNSSOGU-UHFFFAOYSA-N 0.000 description 1
- LPWKFUVWWQYLOD-UHFFFAOYSA-N 9-(dimethylamino)-3-(4-methylphenyl)pyrido[2,3]thieno[2,4-d]pyrimidin-4-one Chemical compound C1=2C(N(C)C)=CN=CC=2SC(C2=O)=C1N=CN2C1=CC=C(C)C=C1 LPWKFUVWWQYLOD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- JAOGFYSXDYNYSX-UHFFFAOYSA-N CC(C)(C(N=CC(Cl)=C1)=C1C(C=CC(Cl)=C1)=C1N1C(C=C2)=CC=C2N(C2)CC2(CNC(CC2)CCC2C(O)=O)F)C1=O Chemical compound CC(C)(C(N=CC(Cl)=C1)=C1C(C=CC(Cl)=C1)=C1N1C(C=C2)=CC=C2N(C2)CC2(CNC(CC2)CCC2C(O)=O)F)C1=O JAOGFYSXDYNYSX-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 229930195713 D-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
- 230000022963 DNA damage response, signal transduction by p53 class mediator Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 229930195710 D‐cysteine Natural products 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101710110793 Homeodomain-interacting protein kinase 2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 230000005913 Notch signaling pathway Effects 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- KZVWEOXAPZXAFB-BQFCYCMXSA-N Temocaprilat Chemical compound C([C@H](N[C@H]1CS[C@@H](CN(C1=O)CC(=O)O)C=1SC=CC=1)C(O)=O)CC1=CC=CC=C1 KZVWEOXAPZXAFB-BQFCYCMXSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- NPUXORBZRBIOMQ-RUZDIDTESA-N [(2R)-1-[[4-[[3-(benzenesulfonylmethyl)-5-methylphenoxy]methyl]phenyl]methyl]-2-pyrrolidinyl]methanol Chemical compound C=1C(OCC=2C=CC(CN3[C@H](CCC3)CO)=CC=2)=CC(C)=CC=1CS(=O)(=O)C1=CC=CC=C1 NPUXORBZRBIOMQ-RUZDIDTESA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- ACAUCRFTFGRVJJ-UHFFFAOYSA-N aniline;morpholine Chemical compound C1COCCN1.NC1=CC=CC=C1 ACAUCRFTFGRVJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- AJRQIXBBIDPNGK-BVSLBCMMSA-N benzyl n-[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](C[C@H]1C(NCC1)=O)C(=O)C=1SC2=CC=CC=C2N=1)C(=O)OCC1=CC=CC=C1 AJRQIXBBIDPNGK-BVSLBCMMSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000006278 bromobenzyl group Chemical group 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- FDKLLWKMYAMLIF-UHFFFAOYSA-N cyclopropane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CC1 FDKLLWKMYAMLIF-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- VCJZTATVUDMNLU-UHFFFAOYSA-N dibromomethylbenzene Chemical compound BrC(Br)C1=CC=CC=C1 VCJZTATVUDMNLU-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940078469 dl- cysteine Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BNKAXGCRDYRABM-UHFFFAOYSA-N ethenyl dihydrogen phosphate Chemical compound OP(O)(=O)OC=C BNKAXGCRDYRABM-UHFFFAOYSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229940124747 fibrosis therapeutics Drugs 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N glutamic acid Chemical compound OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- KUCDOJMOTMEEOF-UHFFFAOYSA-N gtpl6345 Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(SC=2C3=C4NCCOC4=CN=2)=C3N=C1 KUCDOJMOTMEEOF-UHFFFAOYSA-N 0.000 description 1
- FODONWGPMXPGNC-UHFFFAOYSA-N gtpl6346 Chemical compound C1=CC(Cl)=CC=C1N1C(=O)C(SC=2C3=C4NCCOC4=CN=2)=C3N=C1 FODONWGPMXPGNC-UHFFFAOYSA-N 0.000 description 1
- LFUPTQIEOBBAJE-SECBINFHSA-N gtpl6348 Chemical compound C([C@H](O1)C)NC(C2=3)=C1C=NC=3SC(C1=O)=C2N=CN1C1=CC=C(Cl)C=C1 LFUPTQIEOBBAJE-SECBINFHSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000004551 isoquinolin-3-yl group Chemical group C1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- BGXZIBSLBRKDTP-UHFFFAOYSA-N methyl 9-(4-chloroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Cl)C=C1 BGXZIBSLBRKDTP-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- FLCWYEUDIOQXEB-UHFFFAOYSA-N morpholin-4-yl(phenyl)methanone Chemical compound C=1C=CC=CC=1C(=O)N1CCOCC1 FLCWYEUDIOQXEB-UHFFFAOYSA-N 0.000 description 1
- CFPIZMWTMRWZRO-UHFFFAOYSA-N n,n-diethyl-4-nitroaniline Chemical compound CCN(CC)C1=CC=C([N+]([O-])=O)C=C1 CFPIZMWTMRWZRO-UHFFFAOYSA-N 0.000 description 1
- RCSBCWXPGSPJNF-UHFFFAOYSA-N n-[4-[5-[3-chloro-4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl]butyl]-4-(1,8-naphthyridin-2-yl)butanamide Chemical compound C1=C(Cl)C(OC(F)(F)F)=CC=C1C(O1)=NN=C1CCCCNC(=O)CCCC1=CC=C(C=CC=N2)C2=N1 RCSBCWXPGSPJNF-UHFFFAOYSA-N 0.000 description 1
- MUWDEQLPHWVPPA-GOTSBHOMSA-N n-[6-oxo-6-[(3s,4s)-3-[(4-phenoxyphenyl)sulfonylamino]-4-sulfanylpyrrolidin-1-yl]hexyl]acetamide Chemical compound C1N(C(=O)CCCCCNC(=O)C)C[C@H](S)[C@H]1NS(=O)(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 MUWDEQLPHWVPPA-GOTSBHOMSA-N 0.000 description 1
- HBEDNENASUYMPO-LJQANCHMSA-N n-hydroxy-4-[[(2r)-3-oxo-2-(thiophen-2-ylmethyl)-2,4-dihydroquinoxalin-1-yl]methyl]benzamide Chemical compound C1=CC(C(=O)NO)=CC=C1CN1C2=CC=CC=C2NC(=O)[C@H]1CC1=CC=CS1 HBEDNENASUYMPO-LJQANCHMSA-N 0.000 description 1
- XVLGXCOWKCOUGY-UHFFFAOYSA-N n-methyloxolan-2-amine Chemical compound CNC1CCCO1 XVLGXCOWKCOUGY-UHFFFAOYSA-N 0.000 description 1
- SVEUVITYHIHZQE-UHFFFAOYSA-N n-methylpyridin-2-amine Chemical compound CNC1=CC=CC=N1 SVEUVITYHIHZQE-UHFFFAOYSA-N 0.000 description 1
- XTEGVFVZDVNBPF-UHFFFAOYSA-L naphthalene-1,5-disulfonate(2-) Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1S([O-])(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-L 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-N piperazine-1-carboxylic acid Chemical compound OC(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-N 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 1
- MGNVWUDMMXZUDI-UHFFFAOYSA-N propane-1,3-disulfonic acid Chemical compound OS(=O)(=O)CCCS(O)(=O)=O MGNVWUDMMXZUDI-UHFFFAOYSA-N 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- YKEGUYTXACKXKS-IRXDYDNUSA-N tert-butyl (1s,5s)-3-[5-methyl-6-(2-methylpyridin-3-yl)oxypyrimidin-4-yl]oxy-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CC1=NC=CC=C1OC1=NC=NC(OC2C[C@@H]3CC[C@H](N3C(=O)OC(C)(C)C)C2)=C1C YKEGUYTXACKXKS-IRXDYDNUSA-N 0.000 description 1
- JYRWUSXRTGACLY-UHFFFAOYSA-N tert-butyl 4-[[3-(4-methylsulfonylphenyl)-[1,2]oxazolo[4,5-d]pyrimidin-7-yl]oxy]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=NC=NC2=C1ON=C2C1=CC=C(S(C)(=O)=O)C=C1 JYRWUSXRTGACLY-UHFFFAOYSA-N 0.000 description 1
- DYDSKSOVXWWYQZ-UHFFFAOYSA-N tert-butyl cyanate Chemical compound CC(C)(C)OC#N DYDSKSOVXWWYQZ-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- MGEISCKTUGVOHN-UHFFFAOYSA-N tris(2-hydroxyethyl) phosphate Chemical compound OCCOP(=O)(OCCO)OCCO MGEISCKTUGVOHN-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明公开了2,4‑二取代‑5‑氟嘧啶类衍生物,其结构通式如式I所示:其中,R1和R2分别独立选自:R4选自:本发明还公开了所述化合物的制备方法和它们在制备抗肾间质纤维化药物中的用途。
Description
技术领域
肾间质纤维化是一种慢性和进行性的过程,在衰老和慢性肾病中影响肾脏的正常功能,从而危害人类健康。在目前已知的病理机制中,NF-κB、TGF-β/Smad3、Wnt/β-catenin、Notch和p53信号通路在肾间质纤维化的发生发展中具有重要作用。从现有的药物研究结果可知,针对上述一条或两条通道进行药物发现的策略在肾间质纤维化治疗药物的研发领域没有成功的药物上市(Nat Rev Drug Discov,2016,15(8):568;Am J Kidney Dis.2022,doi:10.1053/j.ajkd.2021.11.010)。研究结果表明,尽管上述各通路已被证明是疾病过程中的重要环节,但由于各信号通路之间存在复杂的相互作用,单独抑制其中一条或两条通路会打开与炎症、纤维化相关的其他通路(Front Cell Dev Biol.2021,9:696542)。这种复杂的情况是当前肾间质纤维化治疗药物研发一直没有取得突破的重要原因。因此,单独针对这些下游靶标寻找高效的肾间质纤维化治疗药物并不是理想的策略。
在肾间质纤维化发病过程中,氧化应激、炎症与纤维化是关键性环节,同时针对上述关键环节寻找多通道药物有望避免各通路相互作用,提高药物疗效。然而,从药物设计学的角度来看,设计同时抑制上述五条通路的单一结构抑制剂难度非常大,十分有必要从另一种角度进行探索,以求开辟新的研究领域,为肾间质纤维化治疗药物的研发提供创新性的思路。
John He等人发表文章指出(Nat Med.2012,18(4):580),同源结构域相互作用蛋白激酶2在肾间质小管病变部位高表达,并通过对的调节,参与纤维化和炎症过程。因此,抑制HIPK2可同时调控纤维化和炎症,达到治疗疾病的目的。
文献研究报道的HIPK2抑制剂分类三类(图1):HIPK2激酶抑制剂、HIPK2/SMAD相互作用抑制剂和HIPK2表达抑制剂。TBID(Plos one.2014,9(2):e89176)是HIPK2激酶抑制剂,它通过占据ATP结合口袋抑制HIPK2的激酶活性。除TBID外,其他具有HIPK2激酶抑制活性的化合物均是通过脱靶效应研究发现的,如TAE-226(Nat Med.2012,18(4):580)、CTx-0294857(J.Proteome Res.2013,12:3104)、Sorafenib(Plos one.2015,10(2):e0117757)、GW-5074、Compound C(Biochem.J.2007,408:297)。BT173(J Am Soc Nephrol.2017,28:2133)是一种HIPK2/SMAD相互作用抑制剂,它可以通过阻断HIPK2和Smad3之间的蛋白-蛋白相互作用发挥抗纤维化作用,但无抑制HIPK2的激酶活性。HIPK2表达抑制剂磷酸氯硝柳胺(phosphate niclosamide)(Kidney International.2017,92:612)可以通过干扰Smad3与HIPK2基因的启动子序列结合来抑制HIPK2的转录,从而抑制HIPK2下游内多条信号通路。
发明专利201911152583.9和PCT/CN2020/129308公开了一种含脲基苯并咪唑类衍生物及其制备方法和应用。
发明专利CN106565673公开了一种具有Wnt信号通路抑制活性的5-氟嘧啶杂环化合物,并将其用于治疗或预防因Wnt信号通路失常引起的病症。
发明专利CN105017159公开了一种5-氟-2,4-二取代氨基嘧啶衍生物及其制备方法和抗肿瘤应用,但并未报道其抑制HIPK2激酶及抗肾间质纤维化活性。
因此,到目前为止,尚没有HIPK2抑制剂成功用于临床。鉴于肾间质纤维化疾病的重大临床需求和HIPK2抑制剂的良好前景,本领域迫切需要开发有效的HIPK2抑制剂。
发明内容
本发明涉及药物化学合成领域,具体涉一类2,4-二取代-5-氟嘧啶衍生物,及其制备方法和应用。
一种2,4-二取代-5-氟嘧啶类衍生物,其结构通式如式I所示:
其中,R1和R2可分别独立选自:
R4选自:
X,Y分别独立选自氮原子或碳原子;Z选自氢原子,叔丁氧羰基,C1-C5烷基,C1-C5烷基酰基,C1-C3烷基羟基,C1-C3烷基磺酰基,C1-C3取代苯基,C1-C5烷基酰胺基。
优选的,R1和R2任一为:R4为Z选自氢原子,C1-C5烷基,C1-C5烷基酰基,C1-C3烷基羟基,C1-C3烷基磺酰基,C1-C3取代苯基,C1-C5烷基酰胺基。
优选的,R1和R2任一为:R4为Z为丁基,戊基,异丁基,异戊基,R1和R2另一为:时,X,Y不同时为碳原子。
优选的,R1和R2任一为:R4为Z选自C4-C5烷基,R1和R2另一不为:
优选的,R1和R2任一为:R4为Z为氢,R1和R2另一不为:
优选的,R1和R2任一为:R1和R2另一为:为Z选自氢原子,C4-C5烷基,C1-C3烷基酰基,C1-C3取代苯基,C1-C5烷基酰胺基。
本发明还提供另外一种2,4-二取代-5-氟嘧啶类衍生物,其结构通式如式II或式III所示:
其中,R3为:
R4选自:
X,Y分别独立选自氮原子或碳原子;Z选自氢原子,叔丁氧羰基,C1-C5烷基,C1-C5烷基酰基,C1-C3烷基羟基,C1-C3烷基磺酰基,C1-C3取代苯基,C1-C5烷基酰胺基。
优选的,C1-C5烷基包括甲基,乙基,丙基,丁基,戊基,异丁基,异戊基,异丙基。
优选的,R3为:R4为Z选自氢原子,C1-C3烷基,C1-C5烷基酰基,C1-C3烷基羟基,C1-C3烷基磺酰基,C1-C3取代苯基,C1-C5烷基酰胺基。
优选的,在R3中,R4为时,Z不为叔丁氧羰基。
优选的,式III中的R4为时,Z不为叔丁氧羰基、C4-C5烷基、C4-C5烷基酰基,C4-C5烷基酰胺基。
优选的,C1-C5烷基酰基包括甲酰基,乙酰基,丙酰基,丁酰基,戊酰基,3,3-二甲基-1-丁酰基,异戊酰基。
优选的,C1-C5烷基酰胺基包括甲酰胺基,乙酰胺基,丙酰胺基,丁酰胺基,戊酰胺基,N-叔丁基胺基甲酰基,异戊酰胺基。
优选的,C1-C3烷基羟基包括羟甲基,1-羟基乙基,1-羟基丙基。
优选的,C1-C3烷基磺酰基包括磺酰基甲基,磺酰基乙基,磺酰基丙基。
优选的,C1-C3取代苯基包括苄基,苯乙基,苯丙基。
优选的,上述化合物其药学上可用的盐是盐酸盐、硫酸盐、磷酸盐、高氯酸盐、甲磺酸盐、三氟甲磺酸盐、甲酸盐、乙酸盐、丙酸盐、丁酸盐、马来酸盐、丁二酸盐、三氟乙酸盐、琥珀酸盐、水杨酸盐、DL-天冬氨酸盐、D-天冬氨酸盐、L-天冬氨酸盐、DL-谷氨酸盐、D-谷氨酸盐、L-谷氨酸盐、甘油酸盐、硬脂酸盐、DL-酒石酸盐、D-酒石酸盐、L-酒石酸盐、(±)扁桃酸盐、(R)-(-)扁桃酸盐、(S)-(+)扁桃酸盐、柠檬酸盐、粘酸盐、丙二酸盐、苯甲酸盐、DL-苹果酸盐、(±)乳酸盐、L-(+)-乳酸盐、D-(+)-乳酸盐、扑酸盐、D-α-半乳糖醛酸盐、甘油酸盐、DL-半胱氨酸盐、D-半胱氨酸盐、L-半胱氨酸盐、(4S)-羟基-L-脯氨酸盐、环丙烷-1,1-二羧酸盐、2,2-甲基丙二酸盐、酪氨酸盐、脯氨酸盐、富马酸盐、1-羟基-2-萘甲酸盐、膦酰基乙酸盐、碳酸盐、碳酸氢盐、3-膦酰基丙酸盐、DL-焦谷氨酸盐、D-焦谷氨酸盐、L-焦谷氨酸盐、对甲苯磺酸盐、苯磺酸盐、乙磺酸盐、(±)樟脑磺酸盐、萘磺酸盐、1R-(-)-樟脑磺酸盐、1S-(+)-樟脑磺酸盐、1,5-萘二磺酸盐、1,2-乙烷二磺酸盐、1,3-丙烷二磺酸盐、3-(N-吗啉代)丙烷磺酸盐、联苯基磺酸盐,羟乙基磺酸盐、1-羟基-2-萘磺酸盐、磷酸二氢盐、磷酸氢钾盐、磷酸二钾盐、磷酸钾盐、磷酸氢钠盐、磷酸二钠盐、磷酸钠盐、磷酸二氢钠盐、磷酸钙盐、三代磷酸钙盐、六氟代磷酸盐、乙烯基磷酸盐、2-羟基乙基磷酸盐和苯基磷酸盐。
优选的,具体为以下化合物:
叔丁基-4-(4-((2-(2-氨基-1H-苯并[d]咪唑-1-基)-5-氟嘧啶-4-基)氨基)苯基)哌嗪-1-羧酸酯(化合物6a);
叔丁基-4-(4-((2-((1H-苯并[d]咪唑-2-基)氨基)-5-氟嘧啶-4-基)氨基)苯基)哌嗪-1-羧酸酯(化合物6h);
叔丁基-4-(4-((5-氟-2-(异喹啉-3-基氨基)嘧啶-4-基)氨基)苯基)哌嗪-1-羧酸酯(化合物6b);
叔丁基-4-(4-((5-氟-2-(((四氢呋喃-2-基)甲基)氨基)嘧啶-4-基)氨基)苯基)哌嗪-1-羧酸酯(化合物6c);
叔丁基-4-(4-((5-氟-2-((吡啶-2-基甲基)氨基)嘧啶-4-基)氨基)苯基)哌嗪-1-羧酸酯(化合物6d);
叔丁基-4-(4-((5-氟-2-((4-(甲氧甲酰基)苯基)氨基)吡啶-4-基)氨基)苯基)哌嗪-1-羧酸酯(化合物6e);
1-(5-氟-4-((4-(4-甲基哌嗪-1-基)苯基)氨基)嘧啶-2-基)-1H-苯并[d]咪唑-2-胺(化合物6f);
1-(4-((4-(4-乙基哌嗪-1-基)苯基)氨基)-5-氟嘧啶-2-基)-1H-苯并[d]咪唑-2-胺(化合物6g);
N2-(1H-苯并[d]咪唑-2-基)-N4-(4-(4-乙基哌嗪-1-基)苯基)-5-氟嘧啶-2,4-二胺(化合物6g-1);
1-(5-氟-4-((4-(哌嗪-1-基)苯基)氨基)嘧啶-2-基)-1H-苯并[d]咪唑-2-胺(化合物7a);
5-氟-N2-(异喹啉-3-基)-N4-(4-(哌嗪-1-基)苯基)嘧啶-2,4-二胺(化合物7b);
5-氟-N4-(4-哌嗪-1-基)苯基)-N2-((四氢呋喃-2-基)甲基)嘧啶-2,4-二胺(化合物7c);
5-氟-N4-(4-(哌嗪-1-基)苯基-N2-(吡啶-2-基甲基)嘧啶-2,4-二胺(化合物7d);
甲基-4-((5-氟-4-((4-(哌嗪-1-基)苯基)氨基)嘧啶-2-基)氨基苯甲酸酯(化合物7e);
1-(5-氟-4-((4-(4-异戊基哌嗪-1-基)苯基)氨基)嘧啶-2-基)-1H-苯并[d]咪唑-2-胺(化合物8a);
5-氟-N4-(4-(4-异戊基哌嗪-1-基)苯基)-N2-异喹啉-3-基)嘧啶-2,4-二胺(化合物8b);
5-氟-N4-(4-(4-异戊基哌嗪-1-基)苯基)-N2-((四氢呋喃-2-基)甲基)嘧啶-2,4-二胺(化合物8c);
5-氟-N4-(4-(4-异戊基哌嗪-1-基)苯基)-N2-(吡啶-2-基甲基)嘧啶-2,4-二胺(化合物8d);
甲基-4-((5-氟-4-((4-(4-异戊基哌嗪-1-基)苯基)氨基)嘧啶-2-基)氨基)苯甲酸酯(化合物8e);
叔丁基-4-(5-(2-(2-氨基-1H-苯并[d]咪唑-1-基)-5-氟嘧啶-4-基)吡啶-2-基)哌嗪-1-羧酸酯(化合物11h);
1-(5-氟-4-(6-(哌嗪-1-基)吡啶-3-基)嘧啶-2-基)-1H-苯并[d]咪唑-2-胺(化合物12h);
1-(5-氟-4-(6-(4-异戊基哌嗪-1-基)吡啶-3-基)嘧啶-2-基)-1H-苯并[d]咪唑-2-胺(化合物13h);
N6-(5-氟-4-((4-吗啉苯基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物23a);
N6-(5-氟-4-((4-(吡咯-1-基)苯基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物23b);
N6-(4-((4-(二乙基胺基)苯基)胺基)-5-氟嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物23c);
N6-(4-((4-(二丙基胺基)苯基)胺基)-5-氟嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物23d);
N6-(5-氟-4-((4-(哌啶-1-基)苯基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物23e);
叔丁基-4-(4-((2-((2-(二甲基胺基)-1H-苯并[d]咪唑-6-基)胺基)-5-氟嘧啶-4-基)胺基)苯基)哌嗪-1-羧酸酯(化合物23f);
N6-(4-((4-(二甲基胺基)苯基)胺基)-5-氟嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物23i);
叔丁基-4-(5-((2-((2-(二甲基胺基)-1H-苯并[d]咪唑-6-基)胺基)-5-氟嘧啶-4-基)胺基)吡啶-2-基)哌嗪-1-羧酸酯(化合物23g);
叔丁基-4-(5-((2-((2-(二甲基胺基)-1H-苯并[d]咪唑-6-基)胺基)-5-氟嘧啶-4-基)胺基)吡啶-3-基)哌嗪-1-羧酸酯(化合物23h);
N6-(5-氟-4-((4-(哌嗪-1-基)苯基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物24a);
N6-(5-氟-4-((6-(哌嗪-1-基)吡啶-3-基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物24b);
N6-(5-氟-4-((5-(哌嗪-1-基)吡啶-2-基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物24c);
N6-(5-氟-4-((4-(4-甲基哌嗪-1-基)苯基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物25a);
1-(4-(4-((2-((2-(二甲基胺基)-1H-苯并[d]咪唑-6-基)胺基)-5-氟嘧啶-4-基)胺基)苯基)哌嗪-1-基)乙酮(化合物25b);
N6-(5-氟-4-((4-(4-异丙基哌嗪-1-基)苯基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物25c);
2-(4-(4-((2-((2-(二甲基胺基)-1H-苯并[d]咪唑-6-基)胺基)-5-氟嘧啶-4-基)胺基)苯基)哌嗪-1-基)乙醇(化合物25d);
N6-(4-((4-(4-(乙基磺酰基)哌嗪-1-基)苯基)胺基)-5-氟嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物25e);
N6-(5-氟-4-((4-(4-异戊基哌嗪-1-基)苯基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物25f);
N6-(4-((4-(4-苄基哌嗪-1-基)苯基)胺基)-5-氟嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物25g);
1-(4-(4-((2-((2-(二甲基胺基)-1H-苯并[d]咪唑-6-基)胺基)-5-氟嘧啶-4-基)胺基)苯基)哌嗪-1-基)-3,3-二甲基丁-1-酮(化合物25h);
N-(叔丁基)-4-(4-((2-((2-(二甲基胺基)-1H-苯并[d]咪唑-6-基)胺基)-5-氟嘧啶-4-基)胺基)苯基)哌嗪-1-甲酰胺(化合物25i);
N6-(5-氟-2-((4-(吡咯-1-基)苯基)胺基)嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物29a);
N6-(5-氟-2-((4-(哌嗪-1-基)苯基)胺基)嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物29b);
N6-(5-氟-2-((6-(哌嗪-1-基)吡啶-3-基)胺基)嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物29c);
N6-(2-((4-(二甲基胺基)苯基)胺基)-5-氟嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物29d);
N6-(5-氟-2-((5-(哌嗪-1-基)吡啶-2-基)胺基)嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物29e);
1-(4-(4-((4-((2-(二甲基胺基)-1H-苯并[d]咪唑-6-基)胺基)-5-氟嘧啶-2-基)胺基)苯基)哌嗪-1-基)乙酮(化合物29f);
N6-(5-氟-2-((4-(4-异戊基哌嗪-1-基)苯基)胺基)嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物29g);
N6,N6-(5-氟嘧啶-2,4-二基)双(N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺)(化合物29h)。
本发明还公开了一种2,4-二取代-5-氟嘧啶类衍生物的制备方法,其特征在于包括以下步骤:
2,4-二氯-5-氟-嘧啶先后与不同胺类化合物反应得到化合物I或II,2,4-二氯-5-氟-嘧啶与硼酸酯反应生成的中间体继续与2-氨基苯并咪唑反应得到化合物III。
本发明包含上述2,4-二取代-5-氟嘧啶类衍生物在制备治疗纤维化的药物中的应用。
优选的,所述纤维化为肾间质纤维化。
本发明包含2,4-二取代-5-氟嘧啶类衍生物或其药学上可用的盐,作为抗纤维化的药物。
本发明提供一种药物组合物,包含有效量的化合物、化合物的立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐或它的前药及其药学上可接受的辅料。
所述药学上可接受的辅料包括溶剂、稀释剂、其他液体赋形剂、分散剂或悬浮剂、表面活性剂、等渗剂、增稠剂、乳化剂、防腐剂、固体粘合剂或润滑剂等。
所述药物组合物可以是液体,固体,半固体,凝胶或喷雾剂型。
本发明的化合物或药学上可接受的组合物可以通过任何合适方式给药,可根据疾病的严重程度经口、直肠、肠胃外、脑池内、阴道内、腹膜内、局部给药等向人或其它动物施用以上所述化合物和药学上可接受的组合物。
术语“药学上可接受的盐”是指本发明的化合物的有机盐和无机盐。术语“药学上可接受的”是指物质或组合物必须与包含制剂的其它成分和/或用其治疗的哺乳动物化学上和/或毒理学上相容。
另一方面,本发明所述化合物包括使用各种同位素标记的本发明所定义的化合物,例如,其中存在放射性同位素,如3H,14C和18F的那些化合物,或者其中存在非放射性同位素,如2H和13C的化合物。
附图说明
图1为文献报道具有HIPK2抑制活性的化合物。
图2为实施例16中化合物7a对NRK-49F细胞α-SMA、Fn 1表达的影响。
图3为实施例17中化合物7a对炎症信号通路中P65表达的影响
图4为实施例18中各组小鼠肾组织HE染色(1×),左侧为Sham组,中间为UUO组,右侧为UUO+化合物7a组。
图5为实施例18中各组小鼠肾组织HE染色(200×),左侧为Sham组,中间为UUO组,右侧为UUO+化合物7a组。
图6为实施例18中各组小鼠肾组织损伤评分,左侧为Sham组,中间为UUO组,右侧为UUO+化合物7a组。
图7为实施例18中各组小鼠肾组织masson染色(×1),左侧为Sham组,中间为UUO组,右侧为UUO+化合物7a组。
图8为实施例18中各组小鼠肾组织masson染色(200×),左侧为Sham组,中间为UUO组,右侧为UUO+化合物7a组。
图9各实施例18中组小鼠肾组织masson染色评分,左侧为Sham组,中间为UUO组,右侧为UUO+化合物7a组。
图10为实施例18中化合物25f组的肾组织染色和损伤评分。
具体实施方式
条件和试剂:a.K2CO3,DMSO,90℃,5 h;b.Fe,NH4Cl,EtOH,H2O,reflux,5 h;c.H2O,MeOH,60℃,12h;d.Corresponding amines,Cs2CO3,Xantphos,Pd2(dba)3,1,4-dioxane,N2protection,sealed tube,120℃,12 h;e.TFA,DCM,r.t.,4 h;f.3-Methyl butanal,DCE,AcOH,NaHB(OCOCH3)3,60℃,16 h.
以对氟硝基苯、1-Boc-哌嗪作为起始原料,用二甲亚砜作为反应溶剂,在回流5h的条件下发生亲核取代反应,得到中间体3。然后用铁粉和氯化铵将硝基还原为氨基,得到中间体4。中间体4和2,4-二氯-5-氟嘧啶在甲醇中发生亲核取代反应,得到化合物5。化合物5和各种不同的胺以Cs2CO3为碱,以Xantphos做载体,以Pd2(dba)3做催化剂,以1,4-dioxane做溶剂发生Buchwald–Hartwig偶联反应,得到目标化合物6a-e,6h。化合物6a-e在室温下用三氟乙酸脱Boc,得到目标化合物7a-e。化合物7a-e与异戊醛发生鲍奇还原反应,得到目标化合物8a-e。
条件和试剂:a.K2CO3,DMSO,90℃,5-18 h;b.NH4Cl,Fe,H2O,EtOH,reflux,5 h;c.H2O,MeOH,60℃,12 h;d.Cs2CO3,Xantphos,Pd2(dba)3,1,4-dioxane,N2 protection,sealed tube,120℃,12 h.
以对氟硝基苯,1-甲基哌嗪或者1-乙基哌嗪作为起始原料,以二甲基亚砜作为反应溶剂,90度的条件下反应得到中间体3f-g。以铁粉为还原剂,乙醇和水为反应溶剂,加入适量的氯化铵,回流条件下反应5小时得到还原产物4f-g,然后与2,4-二氯-5-氟嘧啶在甲醇中发生亲核取代反应,得到化合物5f-g。化合物5f-g和2-氨基苯并咪唑以Cs2CO3为碱,以Xantphos做载体,以Pd2(dba)3做催化剂,以1,4-dioxane做溶剂发生Buchwald–Hartwig偶联反应,得到目标化合物6f-g和化合物6g-1。
条件和试剂:a.K2CO3,Pd(dppf)Cl2,H2O:THF=1:5,reflux,5h;b.Xantphos,Pd2(dba)3,Cs2CO3,1,4-dioxane,N2 protection,sealed tube,120℃,12h;c.TFA,DCM,r.t.,4h;d.Trimethyl acetaldehyde,DCE,AcOH,NaHB(OCOCH3)3,60℃,16h.
2-(4-BOC-哌嗪基)吡啶-5-硼酸频哪醇酯在SUZUKI反应条件下(H2O:THF=1:5为溶剂,醋酸钯为催化剂,碳酸钾为碱)与2,4-二氯-5-氟嘧啶反应5h,得到化合物10。化合物10和2-氨基苯并咪唑发生Buchwald–Hartwig偶联反应,得到目标化合物11h。化合物11h在室温下用三氟乙酸脱Boc,得到目标化合物12h。化合物12h与异戊醛发生鲍奇还原反应,得到目标化合物13h。
条件和试剂:a.Correspondingamines,DMSO,K2CO3,90℃,5h or diethylamine,DMSO,K2CO3,50℃,18h;b.Fe,NH4Cl,H2O,EtOH,reflux,5h;c.DCM,Et3N,reflux,4h;d.H2,Pd/C;MeOH,18h;e.MeOH,H2O,60℃,12h;f.17,Pd2(dba)3,Xanphos,Cs2CO3,1,4-dioxane,N2 protection,sealed tube,120℃,12h.
首先对苯并咪唑片段进行合成,以化合物14和15为原料环合得到含硝基的苯并咪唑片段16,在通过氢气还原的方法将硝基还原成氨基合成得到含氨基的苯并咪唑片段17。然后以18a-c作为起始原料,亲核取代反应接入对应脂肪氨基达到对位为硝基的芳香环联脂肪杂环片段。然后对采用铁粉还原的方法对硝基进行还原得到对位为氨基的芳香环联脂肪杂环片段20a-h,20i没有经过此方法合成,直接外购于安耐吉公司。20a-i和原料21在甲醇做溶剂不需要任何碱性环境的条件下发生亲核取代反应得到化合物22a-i,22a-i再和化合物17在以Pd2(dba)3做催化剂,以Xanphos做载体,以Cs2CO3提供碱性环境,以1,4-dioxane做溶剂的条件下发生Buchwald–Hartwig偶联反应得到目标化合物23a-i。其中23f-h脱Boc得到目标化合物24a-c。
条件和试剂:g.DCM,TAF,r.t.,4h;h.for 25a,methyl iodide,ACN,Et3N,-10℃,10min;for 25b,Acetic anhydride,ACN,Et3N,r.t.,2h;for 25c,2-iodopropane,ACN,K2CO3,65℃,16h;for 25d,2-bromoethan-1-ol,ACN,Et3N,r.t.,16h;for 25e,ethanesulfonyl chloride,ACN,Et3N,r.t.,1h;for 25f,Trimethyl acetaldehyde,AcOH,DCE,NaHB(OCOCH3)3,60℃,16h;for 25g,(bromomethyl)benzene,ACN,Et3N,-10℃,10min;for 25h,3,3-dimethylbutanoyl chloride,ACN,Et3N,-10℃,10min;for 25i,2-isocyanato-2-methylpropane,ACN,Et3N,-10℃,10min.
24a与碘甲烷,在负10℃条件下,以乙腈为溶剂,三乙胺为催化剂反应得到化合物25a。24a与醋酸酐,以乙腈为溶剂,三乙胺为催化剂,在室温下反应得到化合物25b。24a与2-碘丙烷,在65℃条件下,以乙腈为溶剂,反应得到化合物25c。24a与2-溴乙醇,以乙腈为溶剂,三乙胺为催化剂,室温条件下反应16h得到化合物25d。24a与乙烷磺酰氯,以乙腈为溶剂,三乙胺为催化剂,室温条件下反应1h得到化合物25e。24a与三甲基乙醛,以二氯乙烷为溶剂,以冰醋酸,三甲氧基硼氢化钠为催化剂,在60℃条件下,反应16h得到化合物25f。24a与溴苄反应,以乙腈为溶剂,三乙胺为催化剂,在负10℃条件下反应10分钟得到化合物25g。24a与3,3-二甲基丁酰氯反应,以乙腈为反应溶剂,三乙胺为催化剂,在负10℃条件下反应10分钟得到化合物25h。24a与叔丁基氰酸酯,以乙腈为反应溶剂,三乙胺为催化剂,在负10℃条件下反应10分钟得到化合物25i。
条件和试剂:a.17,MeOH,H2O,60℃,12h;b.(Boc)2O,DMAP,Et3N,DCM,r.t.,24h;c1.Corresponding amines,Pd2(dba)3,Xanphos,Cs2CO3,1,4-dioxane,N2 protection,sealed tube,120℃,12h;c2.17,Pd2(dba)3,Xanphos,Cs2CO3,1,4-dioxane,N2 protection,sealed tube,120℃,12h;d.DCM,TAF,r.t.,4h;e.for 29f,Acetic anhydride,ACN,Et3N,r.t.,2h;for 29gTrimethylacetaldehyde,AcOH,DCE,NaBH(OCOCH3)3,60℃,16h.
首先化合物17和原料12在甲醇做溶剂不需要任何碱性试剂的条件下发生亲核取代反应得到化合物26,然后与二碳酸二叔丁酯,以DMAP和三乙胺为催化剂,以二氯甲烷为反应溶剂,室温条件下反应24小时得到化合物27。化合物27分别与相应的胺或者化合物17,在以Pd2(dba)3做催化剂,以Xanphos做载体,以Cs2CO3提供碱性环境,以1,4-dioxane做溶剂的条件下发生Buchwald–Hartwig偶联反应得到目标化合物28a-e和28f。对28a-e和28f脱去Boc保护得到目标化合物29a-e和29h。29b和乙酸酐,以乙腈为溶剂,三乙胺为催化剂,室温条件下反应2小时得到化合物29f。29b和三甲基乙醛,以二氯乙烷为反应溶剂,
以冰醋酸,三甲氧基硼氢化钠为催化剂,60℃反应16小时得到化合物29g。
实施例1:叔丁基-4-(4-((2-(2-氨基-1H-苯并[d]咪唑-1-基)-5-氟嘧啶-4-基)氨基)苯基)哌嗪-1-羧酸酯的制备(化合物6a)
化合物5由实验室前期工作合成,经氢谱、质谱确证结构。1H NMR(500MHz,DMSO-d6)δ9.83(s,1H),8.23(d,J=3.5Hz,1H),7.51(d,J=9.1Hz,2H),6.97(d,J=9.1Hz,2H),3.52-3.41(m,4H),3.14-3.03(m,4H),1.42(s,9H).HRMS(ESI)m/z calcd for[C19H23ClFN5O2+H]+:408.1597;found:408.1601[M+H]+。
将化合物5(2.03g,5mmol),2-氨基苯并咪唑(20mmol),Xantphos(0.046g,0.08mmol),Pd2(dba)3(0.018g,0.02mmol),碳酸铯(4.864g,15mmol),加入到含搅拌子的100mL封管中,加入30mL二氧六环(4A分子筛干燥),用氮气置换瓶中空气,拧上盖子,置于超声溶解。放入120℃油浴中反应12h。置于室温冷却后,旋干反应液,用二氯甲烷/水进行萃取,再用二氯甲烷对水层洗涤3次,用无水Na2SO4干燥有机层4h。
抽滤,旋干有机溶剂,得黄绿色固体,用200-300目硅胶柱层析对其分离纯化(DCM:MeOH=40:1),得到白色固体粉末1.169g,收率47%。1H NMR(500MHz,DMSO-d6)δ9.87(s,1H),8.39(d,J=3.4Hz,1H),8.00(d,J=8.0Hz,1H),7.60(s,2H),7.44-7.38(m,2H),7.17-7.12(m,1H),7.07-7.00(m,3H),6.82-6.75(m,1H),3.50(t,J=5.1Hz,4H),3.14(t,J=5.1Hz,4H),1.44(s,9H).13C NMR(125MHz,DMSO-d6)δ154.51,154.35,149.20,143.37,139.86,139.70,131.92,129.53,125.63,123.19,119.23,116.73,115.26,115.18,79.46,49.09,28.55.HRMS(ESI)m/z calcd for[C26H29FN8O2+H]+:505.2476;found:505.2491。
叔丁基-4-(4-((2-((1H-苯并[d]咪唑-2-基)氨基)-5-氟嘧啶-4-基)氨基)苯基)哌嗪-1-羧酸酯的制备(化合物6h)
使用上述实施例1的方法,以2-氨基苯并咪唑为原料,制备得到化合物6h,为白色固体粉末,收率16%。1H NMR(500MHz,DMSO-d6)δ11.60(s,1H),10.95(s,1H),9.54(s,1H),8.16(d,J=3.7Hz,1H),7.64(d,J=8.6Hz,2H),7.43-7.15(m,2H),7.02(dd,J=9.3,3.4Hz,4H),3.51(t,J=5.1Hz,4H),3.14(t,J=5.1Hz,4H),1.43(s,9H).13C NMR(125MHz,DMSO-d6)δ154.37,154.20,150.96,150.87,149.47,148.25,142.63,140.66,140.13,139.97,130.78,124.32,116.68,79.49,49.06,28.55.HRMS(ESI)m/z calcd for[C26H29FN8O2+H]+:505.2476;found:505.2515.
叔丁基-4-(4-((5-氟-2-(异喹啉-3-基氨基)嘧啶-4-基)氨基)苯基)哌嗪-1-羧酸酯的制备(化合物6b)
使用上述实施例1的方法,以2-氨基异喹啉为原料,制备得到化合物6b,为黄色固体粉末,收率86%。1H NMR(500MHz,DMSO-d6)δ9.44(s,1H),9.34(s,1H),9.05(s,1H),8.34(s,1H),8.15(d,J=3.6Hz,1H),7.97(d,J=8.2Hz,1H),7.62(s,1H),7.60-7.54(m,2H),7.49(d,J=8.3Hz,1H),7.41(t,J=7.5Hz,1H),7.01(d,J=8.5Hz,2H),3.53(t,J=4.9Hz,4H),3.14(t,J=5.1Hz,4H),1.45(s,9H).13C NMR(125MHz,DMSO-d6)δ154.96,154.36,151.45,149.20,148.07,140.71,140.55,137.94,131.10,130.69,128.08,126.25,125.07,124.77,124.56,116.71,104.44,79.48,49.25,28.55.HRMS(ESI)m/z calcd for[C28H30FN7O2+H]+:516.2523;found:516.2554.叔丁基-4-(4-((5-氟-2-(((四氢呋喃-2-基)甲基)氨基)嘧啶-4-基)氨基)苯基)哌嗪-1-羧酸酯的制备(化合物6c)
使用上述实施例1的方法,以2-甲胺基四氢呋喃为原料,制备得到化合物6c,为白色固体粉末,收率35%。1H NMR(500MHz,DMSO-d6)δ8.95(s,1H),7.85(d,J=3.9Hz,1H),7.70-7.63(m,2H),6.93-6.87(m,2H),6.61(s,1H),3.97(p,J=6.4Hz,1H),3.79-3.71(m,1H),3.60(q,J=7.4Hz,1H),3.46(t,J=5.0Hz,4H),3.30-3.15(m,2H),3.03(t,J=5.1Hz,4H),1.92-1.72(m,3H),1.56(ddt,J=12.3,7.9,6.4Hz,1H),1.42(s,9H).13C NMR(125MHz,DMSO-d6)δ158.71,154.31,147.12,132.35,122.14,116.70,79.40,77.57,67.46,49.51,45.93,29.12,28.52,25.54.HRMS(ESI)m/z calcd for[C24H33FN6O3+H]+:473.2676;found:473.2723.
叔丁基-4-(4-((5-氟-2-((吡啶-2-基甲基)氨基)嘧啶-4-基)氨基)苯基)哌嗪-1-羧酸酯的制备(化合物6d)
使用上述实施例1的方法,以2-甲胺基吡啶为原料,制备得到化合物6d,为白色固体粉末,收率13%。1H NMR(500MHz,DMSO-d6)δ8.97(s,1H),8.54-8.50(m,1H),7.87(d,J=3.8Hz,1H),7.71(t,J=7.8Hz,1H),7.51(s,2H),7.28(t,J=8.4Hz,2H),7.22(t,J=6.2Hz,1H),6.88-6.73(m,2H),4.48(d,J=6.1Hz,2H),3.46(t,J=4.9Hz,4H),3.01(t,J=5.1Hz,4H),1.42(d,J=2.0Hz,9H).13C NMR(125MHz,DMSO-d6)δ160.54,158.61,154.31,149.17,147.03,136.92,132.18,122.17,120.86,116.62,79.41,49.47,47.22,28.53.HRMS(ESI)m/z calcd for[C25H30FN7O2+H]+:480.2523;found:480.2578.
叔丁基-4-(4-((5-氟-2-((4-(甲氧甲酰基)苯基)氨基)吡啶-4-基)氨基)苯基)哌嗪-1-羧酸酯的制备(化合物6e)
使用上述实施例1的方法,以对氨基苯甲酸甲酯为原料,制备得到化合物6e,为白色固体粉末,收率55%。1H NMR(500MHz,DMSO-d6)δ9.65(s,1H),9.33(s,1H),8.10(d,J=3.6Hz,1H),7.82-7.74(m,4H),7.54(d,J=8.6Hz,2H),6.98(d,J=8.6Hz,2H),3.79(s,3H),3.49(t,J=5.1Hz,4H),3.09(t,J=5.1Hz,4H),1.43(s,9H).13C NMR(125MHz,DMSO-d6)δ166.49,155.37,155.35,154.30,150.74,148.12,146.12,140.49,140.38,140.23,131.18,130.42,124.18,121.34,117.59,116.70,79.44,52.06,49.41,28.52.HRMS(ESI)m/z calcdfor[C27H31FN6O4+H]+:523.2469;found:523.2527.
叔丁基-4-(5-(2-(2-氨基-1H-苯并[d]咪唑-1-基)-5-氟嘧啶-4-基)吡啶-2-基)哌嗪-1-羧酸酯的制备(化合物11h)
2-(4-BOC-哌嗪基)吡啶-5-硼酸频哪醇酯在SUZUKI反应条件下(H2O:THF=1:5为溶剂,醋酸钯为催化剂,碳酸钾为碱)与2,4-二氯-5-氟嘧啶反应5h,旋干溶剂,用水打浆,抽滤得到化合物10直接投入下一步。
使用上述实施例1的方法,以2-氨基苯并咪唑为原料,制备得到化合物11h,为白色固体粉末,收率53%。1H NMR(500MHz,DMSO-d6)δ8.83-8.77(m,2H),8.13(q,J=4.9,4.0Hz,2H),7.63(s,2H),7.21(d,J=7.6Hz,1H),7.10(t,J=7.6Hz,1H),6.98(t,J=7.8Hz,1H),6.94(dd,J=9.3,3.1Hz,1H),3.67-3.62(m,4H),3.46-3.40(m,4H),1.44(s,9H).13C NMR(125MHz,DMSO-d6)δ159.70,154.34,153.29,152.92,151.37,151.26,149.88,149.79,147.12,146.86,143.53,137.90,137.83,131.92,123.63,119.79,117.23,117.17,115.70,114.22,107.10,79.61,44.32,28.53.HRMS(ESI)m/z calcd for[C25H27FN8O2+H]+:491.2319;found:491.2361.
实施例2:1-(5-氟-4-((4-(哌嗪-1-基)苯基)氨基)嘧啶-2-基)-1H-苯并[d]咪唑-2-胺的制备(化合物7a)
将化合物6a(1.2g,15mmol)加入60mL的DCM/TFA=2/1中于150mL的茄形瓶中,室温搅拌4h,用NaOH调pH至碱性,用水洗3次,旋干有机层,得白色固体粉末0.8g,收率83%。1HNMR(500MHz,DMSO-d6)δ9.86(s,1H),8.37(d,J=3.4Hz,1H),7.99(d,J=8.0Hz,1H),7.65(s,2H),7.38(d,J=8.8Hz,2H),7.15(d,J=7.7Hz,1H),7.04(t,J=7.6Hz,1H),6.98(d,J=8.9Hz,2H),6.78(t,J=7.7Hz,1H),3.07(dd,J=6.3,3.7Hz,4H),2.86(dd,J=6.4,3.7Hz,4H).13C NMR(125MHz,DMSO-d6)δ154.54,152.42,150.04,143.93,143.37,141.91,139.74,139.57,131.93,128.82,125.67,123.19,119.20,115.97,115.26,115.23,50.04,46.06.HRMS(ESI)m/z calcd for[C21H21FN8+H]+:405.1951;found:405.1975.
5-氟-N2-(异喹啉-3-基)-N4-(4-(哌嗪-1-基)苯基)嘧啶-2,4-二胺的制备(化合物7b)
使用上述实施例2的方法,以化合物6b为原料,制备得到化合物7b,白色固体粉末,收率83%。1H NMR(500MHz,DMSO-d6)δ9.56(s,1H),9.35-9.31(m,1H),9.07(s,1H),8.34(s,1H),8.17(d,J=3.8Hz,1H),7.96(d,J=8.1Hz,1H),7.60(t,J=7.6Hz,1H),7.55(d,J=8.6Hz,2H),7.47(d,J=8.3Hz,1H),7.41(t,J=7.5Hz,1H),7.01-6.95(m,2H),3.29(s,1H),3.11(t,J=4.9Hz,4H),2.92(dd,J=6.0,3.6Hz,4H).13C NMR(125MHz,DMSO-d6)δ154.98,151.45,150.81,149.18,142.20,140.73,140.57,140.23,137.95,130.73,128.05,126.28,125.05,124.82,124.77,116.08,104.43,49.06,45.86.HRMS(ESI)m/z calcd for[C23H22FN7+H]+:416.1999;found:416.2017.
5-氟-N4-(4-哌嗪-1-基)苯基)-N2-((四氢呋喃-2-基)甲基)嘧啶-2,4-二胺的制备(化合物7c)
使用上述实施例2的方法,以化合物6c为原料,制备得到化合物7c,为白色固体粉末,收率为75%。1H NMR(500MHz,Chloroform-d)δ7.76(d,J=3.2Hz,7.47(d,J=8.4Hz,
2H),6.91(s,1H),6.87(d,J=8.5Hz,2H),5.33(t,J=6.0Hz,1H),4.04(dt,J=11.3,5.1Hz,1H),3.85(q,J=7.3Hz,1H),3.73(q,J=7.3Hz,1H),3.53(dt,J=14.2,5.0Hz,1H),3.31(dt,J=13.2,6.2Hz,1H),3.10–3.05(m,4H),3.00(t,J=4.8Hz,4H),2.16(s,1H),1.94(dt,J=16.6,6.4Hz,1H),1.86(hept,J=6.0Hz,2H),1.58(dq,J=15.2,7.8Hz,1H).13CNMR(125MHz,Chloroform-d)δ158.56,158.53,150.34,150.26,148.35,139.84,139.68,130.76,121.92,116.55,77.92,67.97,50.89,46.10,45.89,28.74,25.78.HRMS(ESI)m/zcalcd for[C19H25FN6O+H]+:373.2152;found:373.2188.
5-氟-N4-(4-(哌嗪-1-基)苯基-N2-(吡啶-2-基甲基)嘧啶-2,4-二胺的制备(化合物7d)
使用上述实施例2的方法,以化合物6d为原料,制备得到化合物7d,为白色固体粉末,收率为75%。1H NMR(500MHz,DMSO-d6)δ9.01(s,1H),8.52(d,J=4.8Hz,1H),7.88(d,J=3.9Hz,1H),7.69(t,J=7.8Hz,1H),7.65-7.40(m,2H),7.40-7.26(m,2H),7.20(t,J=6.2Hz,1H),6.79(s,2H),4.52(d,J=6.1Hz,2H),3.03(t,J=4.8Hz,4H),2.91(t,J=4.8Hz,4H).13CNMR(125MHz,DMSO-d6)δ160.52,158.65,149.13,147.58,141.47,139.54,136.92,131.73,122.17,120.94,116.04,49.62,47.25,45.48.HRMS(ESI)m/z calcd for[C20H22FN7+H]+:380.1999;found:380.2026.
甲基-4-((5-氟-4-((4-(哌嗪-1-基)苯基)氨基)嘧啶-2-基)氨基苯甲酸酯的制备(化合物7e)
使用上述实施例2的方法,以化合物6e为原料,制备得到化合物7e,为白色固体粉末,收率为72%。1H NMR(400MHz,DMSO-d6)δ9.63(s,1H),9.30(d,J=1.7Hz,1H),8.10(d,J=3.7Hz,1H),7.83-7.72(m,4H),7.55-7.47(m,2H),6.99-6.90(m,2H),3.80(s,3H),3.10-3.03(m,4H),2.92-2.85(m,4H).13C NMR(101MHz,DMSO-d6)δ166.51,155.40,155.37,150.78,150.67,148.88,146.14,140.34,140.15,130.49,130.42,124.24,121.34,117.59,115.96,52.10,50.11,45.93.HRMS(ESI)m/z calcd for[C22H23FN6O2+H]+:423.1945;found:423.1968.
1-(5-氟-4-(6-(哌嗪-1-基)吡啶-3-基)嘧啶-2-基)-1H-苯并[d]咪唑-2-胺的制备(化合物12h)
使用上述实施例2的方法,以化合物11h为原料,制备得到化合物12h,为白色固体粉末,收率为92%。1H NMR(400MHz,DMSO-d6)δ8.80(dd,J=15.8,3.0Hz,2H),8.19-8.07(m,2H),7.65(s,2H),7.22(d,J=7.7Hz,1H),7.10(t,J=7.5Hz,1H),6.98(t,J=7.7Hz,1H),6.92(d,J=9.2Hz,1H),3.58(t,J=5.0Hz,4H),2.78(d,J=10.0Hz,4H).13C NMR(101MHz,DMSO-d6)δ159.91,154.35,153.14,152.89,151.30,150.57,149.96,149.86,146.84,146.57,143.50,137.58,131.89,123.56,119.73,116.60,115.65,114.25,106.72,45.76,45.68.HRMS(ESI)m/z calcd for[C20H19FN8+H]+:391.1795;found:391.1826.
实施例3:1-(5-氟-4-((4-(4-异戊基哌嗪-1-基)苯基)氨基)嘧啶-2-基)-1H-苯并[d]咪唑-2-胺的制备(化合物8a)
将化合物7a(0.2g,0.5mmol)和乙酸(0.03g,0.5mmol)加入装有10mLDCE的茄形瓶,60℃搅拌20min。再将异戊醛(0.22g,2.5mmol)和三乙酰氧基硼氢化钠(0.3g,1.5mmol)加入反应液中,60℃搅拌13h。用二氯甲烷和水萃取反应液,水层用再用二氯甲烷洗涤3次直至水层在254nm无荧光,合并有机层,旋干,用200-300目硅胶柱层析进一步分离纯化(DCM:MeOH:Et3N=20:1:1)得白色固体粉末0.1g,收率50%。1H NMR(500MHz,DMSO-d6)δ9.87(s,1H),8.38(d,J=3.4Hz,1H),7.99(d,J=8.0Hz,1H),7.64(s,2H),7.38(d,J=8.5Hz,2H),7.14(d,J=7.7Hz,1H),7.03(t,J=7.5Hz,1H),7.01-6.96(m,2H),6.81-6.74(m,1H),3.15(t,J=5.0Hz,4H),2.53-2.47(m,5H),2.32(t,J=7.6Hz,2H),1.66-1.54(m,J=6.8Hz,1H),1.35(q,J=7.2Hz,2H),0.89(d,J=6.7Hz,6H).13C NMR(125MHz,DMSO-d6)δ154.51,149.39,143.36,139.77,139.60,131.91,128.89,125.63,123.19,119.20,115.98,115.23,56.55,53.30,48.90,35.85,26.32,23.11.HRMS(ESI)m/z calcd for[C26H31FN8+H]+:475.2734;found:475.2762.
5-氟-N4-(4-(4-异戊基哌嗪-1-基)苯基)-N2-异喹啉-3-基)嘧啶-2,4-二胺的制备(化合物8b)
使用上述实施例3的方法,以化合物7b为原料,制备得到化合物8b,为白色固体粉末,收率为72%。1H NMR(500MHz,DMSO-d6)δ9.47(s,1H),9.32(s,1H),9.06(s,1H),8.33(s,1H),8.15(d,J=3.7Hz,1H),7.96(d,J=8.1Hz,1H),7.56(dd,J=7.9,5.6Hz,3H),7.48(d,J=8.3Hz,1H),7.41(t,J=7.5Hz,1H),6.98(d,J=8.5Hz,2H),3.17(t,J=4.9Hz,4H),2.55(t,J=4.9Hz,4H),2.36(t,J=7.6Hz,2H),1.63(dp,J=13.3,6.7Hz,1H),1.39(q,J=7.4Hz,2H),0.91(d,J=6.6Hz,6H).13C NMR(125MHz,DMSO-d6)δ151.40,149.19,137.94,130.67,128.04,126.30,125.07,124.74,115.96,104.43,56.56,53.45,49.05,39.54,35.87,26.36,23.13.HRMS(ESI)m/z calcd for[C28H32FN7+H]+:486.2781;found:486.2826.
5-氟-N4-(4-(4-异戊基哌嗪-1-基)苯基)-N2-((四氢呋喃-2-基)甲基)嘧啶-2,4-二胺的制备(化合物8c)
使用上述实施例3的方法,以化合物7c为原料,制备得到化合物8c,为白色固体粉末,收率为36%。1H NMR(500MHz,Chloroform-d)δ7.81(d,J=3.4Hz,1H),7.51(d,J=8.4Hz,2H),6.93(d,J=8.4Hz,2H),6.60(s,1H),5.17(d,J=6.2Hz,1H),4.08(p,J=6.4Hz,1H),3.89(q,J=7.3Hz,1H),3.77(q,J=7.3Hz,1H),3.57(dt,J=10.4,4.9Hz,1H),3.35(dt,J=13.2,6.1Hz,1H),3.20(t,J=4.9Hz,4H),2.63(t,J=4.9Hz,4H),2.42(t,J=7.9Hz,2H),1.98(dt,J=12.1,6.6Hz,1H),1.92(d,J=6.7Hz,1H),1.89(d,J=7.1Hz,1H),1.64(dt,J=13.9,7.0Hz,2H),1.45(q,J=7.5Hz,2H),0.94(d,J=6.6Hz,6H).13C NMR(125MHz,Chloroform-d)δ158.50,150.27,147.91,130.56,121.75,116.54,68.06,57.05,53.37,49.64,45.87,35.91,28.73,26.73,25.84,22.76.HRMS(ESI)m/z calcd for[C24H35FN6O+H]+:443.2935;found:443.2966.5-氟-N4-(4-(4-异戊基哌嗪-1-基)苯基)-N2-(吡啶-2-基甲基)嘧啶-2,4-二胺的制备(化合物8d)
使用上述实施例3的方法,以化合物7d为原料,制备得到化合物8d,为白色固体粉末,收率为39%。1H NMR(400MHz,Chloroform-d)δ8.59(dd,J=5.3,2.9Hz,1H),7.88-7.81(m,1H),7.63(ddq,J=9.6,5.4,1.8Hz,1H),7.46(dd,J=9.1,3.0Hz,2H),7.32(d,J=7.9Hz,1H),7.22–7.14(m,1H),6.94-6.85(m,2H),6.62(dd,J=11.6,4.0Hz,1H),5.91-5.78(m,1H),3.20(dt,J=6.2,3.2Hz,4H),2.68–2.61(m,4H),2.44(td,J=7.7,3.2Hz,2H),1.63(dp,J=13.3,6.7Hz,1H),1.45(dd,J=9.5,6.1Hz,2H),1.27(d,J=4.2Hz,2H),0.94(dd,J=6.6,1.3Hz,6H).13C NMR(101MHz,Chloroform-d)δ154.96,149.07,147.77,139.84,139.68,136.54,130.43,126.07,121.59,121.46,120.27,116.57,116.08,56.94,53.19,49.44,35.62,29.69,29.43,26.72,23.35,22.73.HRMS(ESI)m/z calcd for[C25H32FN7+H]+:450.2781;found:450.2808.
甲基-4-((5-氟-4-((4-(4-异戊基哌嗪-1-基)苯基)氨基)嘧啶-2-基)氨基)苯甲酸酯的制备(化合物8e)
使用上述实施例3的方法,以化合物7e为原料,制备得到化合物8e,为白色固体粉末,收率为57%。1H NMR(500MHz,Chloroform-d)δ7.98–7.91(m,3H),7.63-7.57(m,2H),7.48-7.43(m,2H),7.42(s,1H),6.99-6.94(m,2H),6.80(d,J=2.9Hz,1H),3.90(s,3H),3.24(t,J=5.0Hz,4H),2.65(t,J=4.9Hz,4H),2.44(dd,J=9.3,6.6Hz,2H),1.70-1.58(m,J=6.8Hz,1H),1.46(q,J=7.4Hz,2H),0.95(d,J=6.6Hz,6H).13C NMR(125MHz,Chloroform-d)δ166.96,148.81,144.36,139.73,139.58,130.76,129.25,123.30,122.84,117.34,116.37,57.04,53.32,51.81,49.41,35.91,26.72,22.77.HRMS(ESI)m/z calcdfor[C27H33FN6O2+H]+:493.2727;found:493.2754.
1-(5-氟-4-(6-(4-异戊基哌嗪-1-基)吡啶-3-基)嘧啶-2-基)-1H-苯并[d]咪唑-2-胺的制备(化合物13h)
使用上述实施例3的方法,以化合物12h为原料,制备得到化合物13h,为黄色固体粉末,收率为54%。1H NMR(400MHz,Chloroform-d)δ9.08(d,J=2.5Hz,1H),8.52(d,J=3.4Hz,1H),8.36(d,J=8.0Hz,1H),8.30(dd,J=9.1,2.5Hz,1H),7.44(d,J=7.8Hz,1H),7.25(t,J=7.6Hz,1H),7.14(t,J=7.7Hz,1H),6.86(s,2H),6.78(d,J=9.2Hz,1H),3.82-3.75(m,4H),2.60(t,J=5.1Hz,4H),2.48-2.39(m,2H),1.72-1.58(m,J=6.6Hz,1H),1.46(q,J=7.1Hz,2H),0.95(d,J=6.6Hz,6H).13C NMR(101MHz,Chloroform-d)δ159.84,153.77,153.07,150.49,150.35,150.25,145.50,145.23,142.52,137.64,131.93,123.73,120.49,116.14,114.49,106.10,57.01,53.05,44.68,35.85,26.67,22.76.HRMS(ESI)m/zcalcd for[C25H29FN8+H]+:461.2577;found:461.2616.
实施例4:1-(5-氟-4-((4-(4-甲基哌嗪-1-基)苯基)氨基)嘧啶-2-基)-1H-苯并[d]咪唑-2-胺的制备(化合物6f)
以对氟硝基苯、2f-g作为起始原料,在二甲亚砜为溶剂,回流的条件下反应5h发生亲核取代反应得到中间体3f-g。然后采用铁粉还原的方法对硝基进行还原得到对位为氨基的中间体4f-g。中间体4g-f和2,4-二氯-5-氟嘧啶在甲醇中发生亲核取代反应得到化合物5f-g。前三步合成比较简单,且反应完成后直接析出固体,因此直接抽滤得到产物未经打谱确证直接投于下一步。将化合物5f(2g,6mmol),2-氨基苯并咪唑(1.655g,12mmol),Pd2(dba)3(0.285g,0.28mmol),碳酸铯(3.038g,9.3mmol),Xantphos(0.180g,0.31mmol)加入120mL耐压瓶中,加入50mL经过4A分子筛干燥过的二氧六环,加入到含搅拌子的100mL封管中,加入30mL二氧六环(4A分子筛干燥),用氮气置换瓶中空气,拧上盖子,置于超声溶解。放入120℃油浴中反应12h。置于室温冷却后,旋干反应液,用二氯甲烷/水进行萃取,萃取3次,用无水Na2SO4干燥有机层4h。抽滤,旋干有机溶剂,得黄绿色固体,用200-300目硅胶柱层析对其分离纯化(DCM:MeOH=40:1),白色固体粉末,收率46%。1HNMR(500MHz,DMSO-d6)δ9.86(s,1H),8.39(dd,J=3.5,1.6Hz,1H),7.97(d,J=8.0Hz,1H),7.60(s,2H),7.41 -7.36(m,2H),7.14(d,J=7.8Hz,1H),7.07-6.98(m,3H),6.77(t,J=7.7Hz,1H),3.21-3.15(m,4H),2.49(s,4H),2.25(d,J=1.6Hz,3H).13C NMR(125MHz,DMSO-d6)δ154.49,149.34,143.36,141.66,139.81,139.61,131.91,128.95,125.66,123.19,119.20,116.07,115.25,115.21,55.02,48.72,46.20.HRMS(ESI)m/z calcd for[C22H23FN8+H]+:419.2108;found:419.2134.
1-(4-((4-(4-乙基哌嗪-1-基)苯基)氨基)-5-氟嘧啶-2-基)-1H-苯并[d]咪唑-2-胺的制备(化合物6g)
使用上述实施例4的方法,以化合物5g为原料,制备得到化合物6g,为白色固体粉末,收率54%。1H NMR(400MHz,DMSO-d6)δ9.79(s,1H),8.36(d,J=3.5Hz,1H),7.99(d,J=8.0Hz,1H),7.55(s,2H),7.39(d,J=8.5Hz,2H),7.15(d,J=7.7Hz,1H),7.04(t,J=7.6Hz,1H),6.99(d,J=8.6Hz,2H),6.78(t,J=7.7Hz,1H),3.20-3.15(m,4H),2.56(t,J=5.0Hz,4H),2.42(q,J=7.2Hz,2H),1.06(t,J=7.2Hz,3H).13C NMR(101MHz,DMSO-d6)δ154.50,149.35,143.36,139.80,139.60,131.90,128.95,125.66,123.20,119.20,116.03,115.23,52.73,52.09,48.79,12.39.HRMS(ESI)m/z calcd for[C23H25FN8+H]+:433.2264;found:433.2289.N2-(1H-苯并[d]咪唑-2-基)-N4-(4-(4-乙基哌嗪-1-基)苯基)-5-氟嘧啶-2,4-二胺(化合物6g-1)
使用上述实施例4的方法,以化合物5g为原料,制备得到化合物6g-1,为白色固体粉末,收率30%。1H NMR(500MHz,DMSO-d6)δ11.44(s,1H),9.57(s,1H),8.17(s,1H),7.52(d,J=8.3Hz,3H),7.38-7.34(m,1H),7.02(s,2H),6.97(d,J=8.5Hz,3H),3.40(s,4H),2.38(q,J=7.3Hz,4H),1.04(t,J=7.3Hz,5H).13C NMR(125MHz,DMSO-d6)δ154.19,151.19,151.10,149.60,148.62,142.59,140.62,129.79,115.89,52.93,52.14,48.66,12.46.HRMS(ESI)m/zcalcd for[C23H25FN8+H]+:433.2264;found:433.2289.
实施例5:N,N-二甲基-6-硝基-1H-苯并[d]咪唑-2-胺(化合物16)
将二氯亚甲基二甲基氯化铵(19.44g,120mmol)溶于300mL的DCM中于500mL茄型瓶中,加入4-硝基邻苯二胺(15.30g,100mmol),将茄形瓶放于室温搅拌,茄形瓶上放置回流冷凝管。将三乙胺(30.30g,300mmol)加到恒压滴液漏斗中,用气球封住恒压滴液漏斗的瓶口,将其插入回流冷凝管上,各个衔接口都用封口膜封好。缓慢向茄形瓶中滴加三乙胺,20min滴加完毕。升温至回流继续反应4h。旋干反应液,得黄白色固体。用甲醇重结晶得黄白色固体18.1g。收率88%。1H NMR(500MHz,DMSO-d6)δ13.91(s,1H),8.16(dd,J=8.7,2.0Hz,1H),8.11(d,J=1.9Hz,1H),7.55(d,J=8.7Hz,1H),3.28(s,6H).HRMS(ESI)m/z calcd for[C9H10N4O2+H]+:207.0877;found:207.0877[M+H]+.
实施例6:N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物17)
将N,N-二甲基-5-硝基-1H-苯并[d]咪唑-2-胺(2.06g,10mmol)溶于40mL的MeOH中于100mL的氢化仪专用反应容器中,加入含量10%的钯碳(含水约55%)0.20g。在0.4MPa氢气环境下室温搅拌反应18h。抽滤除去钯碳,旋干滤液,得灰固体。用甲醇重结晶得灰色固体1.45g。收率82%。1H NMR(500MHz,DMSO-d6)δ7.05(d,J=8.4Hz,1H),6.69(s,1H),6.50(d,J=8.4Hz,1H),3.18(s,6H).HRMS(ESI)m/z calcd for[C9H12N4+H]+:177.1135;found:117.1107[M+H]+.
实施例7:4-(4-硝基苯基)吗啉(化合物19a)
将对氟硝基苯(7.05g,50mmol),吗啉(5.22g,60mmol)加入250mL茄型瓶中,加入碳酸钾(10.35g,75mmol)于90℃下反应5h。之后放于室温冷却,冷却到室温后,用乙酸乙酯萃取,有机层再水洗2次,再用饱和NaCl溶液洗涤有机层1次,无水Na2SO4干燥有机层并放置4h。抽滤,旋干有机溶剂,得黄色固体。用乙酸乙酯重结晶得黄色结晶19a共9.5g,收率91%。1HNMR(500MHz,DMSO-d6)δ8.08(d,J=9.5Hz,2H),7.04(d,J=9.5Hz,2H),3.76–3.70(m,4H),3.44–3.38(m,4H).HRMS(ESI)m/z calcd for[C10H12N2O3+H]+:209.0921;found:209.0921[M+H]+.
1-(4-硝基苯基)吡咯(化合物19b)
使用上述实施例7的方法,以化合物18b为原料,制备得到化合物19b,收率90%,黄色固体。1H NMR(500MHz,DMSO-d6)δ8.04(d,J=9.4Hz,2H),6.60(d,J=9.4Hz,2H),3.37(t,J=6.7Hz,4H),2.04–1.94(m,4H).HRMS(ESI)m/z calcd for[C10H12N2O2+H]+:193.0972;found:193.0972[M+H]+.
N,N-二乙基-4-硝基苯胺(化合物19c)
使用上述实施例7的方法,以化合物18c为原料,制备得到化合物19c,收率88%,黄色固体。1H NMR(500MHz,DMSO-d6)δ8.03(d,J=9.5Hz,2H),6.75(d,J=9.5Hz,2H),3.48(q,J=7.1Hz,4H),1.14(t,J=7.1Hz,6H).HRMS(ESI)m/z calcd for[C10H14N2O2+H]+:195.1128;found:195.1131[M+H]+.
4-硝基-N,N-二丙基苯胺(化合物19d)
使用上述实施例7的方法,以化合物18d为原料,制备得到化合物19d,收率87%,黄色固体。1H NMR(500MHz,DMSO-d6)δ8.01(d,J=9.4Hz,2H),6.75(d,J=9.5Hz,2H),3.47–3.34(m,4H),1.66–1.46(m,4H),0.91(t,J=7.3Hz,6H).HRMS(ESI)m/z calcd for[C12H18N2O2+H]+:223.1441;found:223.1445[M+H]+.
1-(4-硝基苯基)哌啶(化合物19e)
使用上述实施例7的方法,以化合物18e为原料,制备得到化合物19e,收率90%,黄色固体。1H NMR(500MHz,DMSO-d6)δ8.02(d,J=9.5Hz,2H),6.98(d,J=9.6Hz,2H),3.54–3.44(m,4H),1.69–1.60(m,2H),1.57(m,4H).HRMS(ESI)m/z calcd for[C11H14N2O2+H]+:207.1128;found:207.1133[M+H]+.
叔丁基-4-(4-硝基苯基)哌嗪-1-羧酸酯(化合物19f)
使用上述实施例7的方法,以化合物18f为原料,制备得到化合物19f,收率92%,黄色固体。1H NMR(500MHz,DMSO-d6)δ8.07(d,J=9.4Hz,2H),7.01(d,J=9.5Hz,2H),3.48(m,8H),1.43(s,9H).HRMS(ESI)m/z calcd for[C15H21N3O4+Na]+:330.1426;found:330.1424[M+Na]+.
叔丁基-4-(5-硝基吡啶-2-基)哌嗪-1-羧酸酯(化合物19g)
使用上述实施例7的方法,以化合物18g为原料,制备得到化合物19g,收率90%,黄色固体。1H NMR(500MHz,DMSO-d6)δ8.97(d,J=2.7Hz,1H),8.25(dd,J=9.6,2.8Hz,1H),6.95(t,J=11.9Hz,1H),3.91–3.66(m,4H),3.61–3.38(m,4H),1.43(s,9H).HRMS(ESI)m/zcalcd for[C14H20N4O4+Na]+:331.1377;found:331.1382[M+Na]+.
叔丁基-4-(5-硝基吡啶-2-基)哌嗪-1-羧酸酯(化合物19h)
使用上述实施例7的方法,以化合物18h为原料,制备得到化合物19h,收率80%,黄色固体。1H NMR(500MHz,DMSO-d6)δ8.24(d,J=2.9Hz,1H),8.16(d,J=9.2Hz,1H),7.46(dd,J=9.2,3.0Hz,1H),3.51(dd,J=14.0,5.6Hz,8H),1.43(s,9H).HRMS(ESI)m/zcalcd for[C14H20N4O4+Na]+:309.1557;found:309.1571[M+H]+.
实施例8:4-吗啉苯胺(化合物20a)
将4-吗啉硝基苯(6.24g,30mmol),铁粉(8.40g,150mmol),氯化铵(7.95g,150mmol)加入250mL茄型瓶中,加入乙醇/水=5/1的溶剂120mL回流反应5h。之后放于室温冷却,冷却到室温后,用装有硅藻土的漏斗抽滤,滤液中加入少量亚硫酸钠以防产物被空气中氧气氧化。低温旋蒸出溶剂中的乙醇,用二氯甲烷/甲醇=10/1的溶剂和水萃取,再用二氯甲烷/甲醇=10/1的溶剂洗涤水溶液3次,合并有机层,无水Na2SO4干燥有机层并放置4h。抽滤出去硫酸钠,旋干有机溶剂,得灰色油状物。共4.5g,收率84%。因为此产物在空气中易氧化,故直接投下一步。20b-20h采用和20a相同的方法制备,同样未经结构确证直接投下一步。
实施例9:2-氯-5-氟-N-(4-吗啉苯基)嘧啶-4-胺(化合物22a)
将4-吗啉苯胺(3.56g,20mmol),2,4-二氯-5-氟嘧啶(4.65g,28mmol),加入250mL茄型瓶中,加入甲醇/水=1/1的溶剂120mL,60℃反应12h。之后放于室温过夜,瓶中有白色固体析出,抽滤得灰白色固体,用甲醇重结晶得灰白色固体5.0g,收率81%。1H NMR(500MHz,DMSO-d6)δ9.83(s,1H),8.24(d,J=3.5Hz,1H),7.50(d,J=9.0Hz,2H),6.97(d,J=9.1Hz,2H),3.89–3.53(m,4H),3.22–2.92(m,4H).HRMS(ESI)m/z calcd for[C14H14ClFN4O+H]+:309.0913;found:309.0923[M+H]+.
2-氯-5-氟-N-(4-(吡咯-1-基)苯基)嘧啶-4-胺(化合物22b)
使用上述实施例9的方法,以化合物20b为原料,制备得到化合物22b,收率77%,白色固体。1H NMR(500MHz,DMSO-d6)δ9.71(s,1H),8.17(d,J=3.6Hz,1H),7.40(d,J=8.9Hz,2H),6.53(d,J=9.0Hz,2H),3.21(t,J=6.5Hz,4H),2.06–1.78(m,4H).HRMS(ESI)m/zcalcd for[C14H14ClFN4+H]+:293.0964;found:293.0976[M+H]+.
N1-(2-氯-5-氟嘧啶-4-基)-N4,N4-二乙基苯-1,4-二胺(化合物22c)
使用上述实施例9的方法,以化合物20c为原料,制备得到化合物22c,收率81%,白色固体。1H NMR(500MHz,DMSO-d6)δ9.70(s,1H),8.19(d,J=3.6Hz,1H),7.38(d,J=9.1Hz,2H),6.67(d,J=9.1Hz,2H),3.34(t,J=7.0Hz,4H),1.09(t,J=7.0Hz,6H).HRMS(ESI)m/zcalcd for[C14H16ClFN4+H]+:295.1120;found:295.1131[M+H]+.
N1-(2-氯-5-氟嘧啶-4-基)-N4,N4-二丙基苯-1,4-二胺(化合物22d)
使用上述实施例9的方法,以化合物20d为原料,制备得到化合物22d,收率75%,黄色油状物。1H NMR(500MHz,DMSO-d6)δ9.70(s,1H),8.18(d,J=3.6Hz,1H),7.37(d,J=9.0Hz,2H),6.64(d,J=9.1Hz,2H),3.29–3.16(m,4H),1.61–1.46(m,4H),0.89(t,J=7.4Hz,6H).HRMS(ESI)m/z calcd for[C16H20ClFN4+H]+:323.1433;found:323.1454[M+H]+.
2-氯-5-氟-N-(4-哌啶-1-基)苯基)嘧啶-4-胺(化合物22e)
使用上述实施例9的方法,以化合物20e为原料,制备得到化合物22e,收率83%,白色固体。1H NMR(500MHz,DMSO-d6)δ9.80(s,1H),8.22(d,J=3.5Hz,1H),7.46(d,J=8.9Hz,2H),6.93(d,J=9.0Hz,2H),3.18–3.05(m,4H),1.66–1.56(m,4H),1.56–1.47(m,2H).HRMS(ESI)m/z calcd for[C15H16ClFN4+H]+:307.1120;found:307.1135[M+H]+.
叔丁基-1-(4-((2-氯-5-氟嘧啶-4-基)氨基)苯基)哌嗪-4-羧酸酯(化合物22f)
使用上述实施例9的方法,以化合物20f为原料,制备得到化合物22f,收率85%,白色固体。1H NMR(500MHz,DMSO-d6)δ9.83(s,1H),8.23(d,J=3.5Hz,1H),7.51(d,J=9.1Hz,2H),6.97(d,J=9.1Hz,2H),3.52–3.41(m,4H),3.14–3.03(m,4H),1.42(s,9H).HRMS(ESI)m/z calcd for[C19H23ClFN5O2+H]+:408.1597;found:408.1601[M+H]+.
叔丁基-4-(5-((2-氯-5-氟嘧啶-4-基)氨基)吡啶-2-基)哌嗪-1-羧酸酯(化合物22g)
使用上述实施例9的方法,以化合物20g为原料,制备得到化合物22g,收率75%,白色固体。1H NMR(500MHz,DMSO-d6)δ9.90(s,1H),8.34(d,J=2.7Hz,1H),8.26(d,J=3.4Hz,1H),7.78(dd,J=9.1,2.7Hz,1H),6.91(d,J=9.1Hz,1H),3.46(m,8H),1.43(s,9H).HRMS(ESI)m/z calcd for[C18H22ClFN6O2+H]+:409.1550;found:409.1557[M+H]+.
叔丁基-4-(6-((2-氯-5-氟嘧啶-4-基)氨基)吡啶-3-基)哌嗪-1-羧酸酯(化合物22h)
使用上述实施例9的方法,以化合物20h为原料,制备得到化合物22h,收率72%,白色固体。1H NMR(400MHz,DMSO-d6)δ10.25(s,1H),8.31(d,J=3.3Hz,1H),8.11(d,J=2.9Hz,1H),7.78(d,J=9.0Hz,1H),7.49(dd,J=9.1,3.0Hz,1H),3.57–3.41(m,4H),3.28–3.01(m,4H),1.42(s,9H).HRMS(ESI)m/z calcd for[C18H22ClFN6O2+H]+:409.1550;found:409.1581[M+H]+.
N1-(2-氯-5-氟嘧啶-4-基)-N4,N4-二甲基苯-1,4-二胺(化合物22i)
使用上述实施例9的方法,以化合物20i为原料,制备得到化合物22i,收率79%,白色固体。1H NMR(500MHz,DMSO-d6)δ9.75(s,1H),8.20(d,J=3.6Hz,1H),7.42(d,J=9.0Hz,2H),6.75(d,J=9.1Hz,2H),2.89(s,6H).HRMS(ESI)m/z calcd for[C12H12ClFN4+H]+:267.0807;found:267.0817[M+H]+.
实施例10:N6-(5-氟-4-((4-吗啉苯基)氨基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物23a)
将化合物22a(2.53g,8mmol),化合物9(1,4g,8mmol),Pd2(dba)3(0.18g,0.02mmol),Xanphos(0.46g,0.08mmol),碳酸铯(4.89g,15mmol)加入120mL耐压瓶中,加入50mL二氧六环,加入搅拌子,用氮气置换瓶中空气,封好口后超声使原料尽可能溶解于溶剂中。放入120℃油浴中反应12h。之后放于室温冷却,冷却到室温后,旋干反应液,用二氯甲烷/水进行萃取,再用二氯甲烷对水层洗涤2次,无水Na2SO4干燥有机层并放置4h。抽滤,旋干有机溶剂,得黑色油状物,用硅胶柱层析对其分离纯化(DCM:MeOH:Et3N=200:1:1),得到白色固体2.34g,收率65%。1H NMR(500MHz,DMSO-d6)δ11.14(s,1H),9.07(s,1H),8.83(s,1H),7.98(d,J=3.7Hz,1H),7.67(d,J=8.9Hz,2H),7.57(s,1H),7.13(d,J=8.1Hz,1H),7.01(d,J=8.4Hz,1H),6.89(d,J=8.9Hz,2H),3.83–3.67(m,4H),3.11–3.04(m,4H),3.03(s,6H).13C NMR(125MHz,DMSO-d6)δ157.17,156.76,156.74,150.10,150.01,147.44,141.70,140.36,140.21,139.75,134.03,131.69,122.63,115.80,113.18,66.62,49.43,38.56.HRMS(ESI)m/z calcd for[C23H25FN8O+H]+:449.2208;found:449.2211[M+H]+.
N6-(5-氟-4-((4-(吡咯-1-基)苯基)氨基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物23b)
使用上述实施例10的方法,以化合物22b为原料,制备得到化合物23b,收率62%,灰白色固体。1H NMR(500MHz,DMSO-d6)δ11.05(s,1H),8.92(s,1H),8.74(s,1H),7.94(d,J=3.4Hz,1H),7.59(s,1H),7.57(d,J=8.4Hz,2H),7.16(d,J=8.4Hz,1H),7.00(d,J=8.3Hz,1H),6.51(d,J=8.4Hz,2H),3.21(m,4H),3.03(s,6H),1.94(m 4H).13C NMR(125MHz,133.96,127.96,123.37,112.83,111.87,47.53,38.02,24.80.HRMS(ESI)m/z calcd for[C23H25FN8+H]+:433.2259;found:443.2261[M+H]+.
N6-(4-((4-(二乙基氨基)苯基)氨基)-5-氟嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物23c)
使用上述实施例10的方法,以化合物22c为原料,制备得到化合物23c,收率65%,灰白色固体。1H NMR(500MHz,DMSO-d6)δ13.10(s,1H),9.16(s,1H),9.05(s,1H),8.00(s,1H),7.83(s,1H),7.51(m,3H),7.20(d,J=8.6Hz,1H),6.66(s,2H),3.32(d,J=5.3Hz,4H),3.22(s,6H),1.08(t,J=6.9Hz,6H).13C NMR(125MHz,DMSO-d6)δ155.99,151.44,150.54,150.44,142.19,140.25,139.46,137.34,131.32,125.66,123.88,114.96,112.27,111.05,102.42,44.30,39.29,12.91.HRMS(ESI)m/z calcd for[C23H27FN8+H]+:435.2415;found:435.2420[M+H]+.
N6-(4-((4-(二丙基氨基)苯基)氨基)-5-氟嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物23d)
使用上述实施例10的方法,以化合物22d为原料,制备得到化合物23d,收率61%,灰白色固体。1H NMR(500MHz,DMSO-d6)δ11.22(d,J=29.3Hz,1H),8.93(s,1H),8.73(d,J=32.5Hz,1H),7.92(s,1H),7.55(m,3H),7.12(m,1H),6.98(m,1H),6.58(d,J=6.9Hz,2H),3.28–3.14(m,4H),3.02(s,6H),1.63–1.42(m,4H),0.88(t,J=7.3Hz,6H).(互变异构)13CNMR(125MHz,DMSO-d6)δ157.70,157.11,156.80,150.25,150.17,144.81,144.40,141.72,141.70,139.84,139.74,139.57,139.41,134.78,133.25,130.23,127.78,123.41,114.35,113.79,112.06,111.79,108.15,107.60,101.83,52.72,38.64,20.54,11.73.HRMS(ESI)m/z calcd for[C25H31FN8+H]+:463.2728;found:463.2732[M+H]+.
N6-(5-氟-4-((4-(哌啶-1-基)苯基)氨基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物23e)
使用上述实施例10的方法,以化合物22e为原料,制备得到化合物23e,收率70%,灰白色固体。1H NMR(500MHz,DMSO-d6)δ9.03(s,1H),8.80(s,1H),7.98(d,J=3.0Hz,1H),7.64(d,J=8.4Hz,2H),7.58(s,1H),7.12(d,J=8.3Hz,1H),7.02(d,J=8.3Hz,1H),6.87(d,J=8.4Hz,2H),3.12–3.05(m,4H),3.04(s,6H),1.63(s,4H),1.52(d,J=5.0Hz,2H).13CNMR(125MHz,DMSO-d6)δ157.35,156.77,150.10,150.02,148.19,141.69,140.32,140.17,139.74,133.88,131.12,122.62,116.51,113.15,113.09,50.62,38.55,25.78,24.25.HRMS(ESI)m/z calcd for[C24H27FN8+H]+:447.2415;found:447.2417[M+H]+.
叔丁基-4-(4-((2-((2-(二甲基氨基)-1H-苯并[d]咪唑-6-基)氨基)-5-氟嘧啶-4-基)氨基)苯基)哌嗪-1-羧酸酯(化合物23f)
使用上述实施例10的方法,以化合物22f为原料,制备得到化合物23f,收率69%,灰白色固体。1H NMR(500MHz,DMSO-d6)δ9.08(s,1H),8.80(s,1H),7.99(d,J=3.2Hz,1H),7.68(d,J=8.5Hz,2H),7.60(s,1H),7.16(d,J=8.4Hz,1H),7.04(d,J=8.4Hz,1H),6.90(d,J=8.5Hz,2H),3.48(m,4H),3.05(m,10H),1.44(s,9H).13C NMR(125MHz,DMSO-d6)δ156.79,156.74,150.10,150.01,147.29,141.73,140.29,139.78,134.16,132.04,122.60,116.79,113.19,111.39,104.43,79.36,49.55,38.61,28.55.HRMS(ESI)m/z calcd for[C28H34FN9O2+H]+:548.2892;found:548.2898[M+H]+.
叔丁基-4-(5-((2-((2-(二甲基氨基)-1H-苯并[d]咪唑-6-基)氨基)-5-氟嘧啶-4-基)氨基)吡啶-2-基)哌嗪-1-羧酸酯(化合物23g)
使用上述实施例10的方法,以化合物22g为原料,制备得到化合物23g,收率49%,浅黄色固体。1H NMR(500MHz,DMSO-d6)δ11.19(s,1H),9.17(s,1H),8.90(s,1H),8.53(s,1H),7.99(d,J=10.7Hz,2H),7.58(s,1H),7.14(d,J=8.3Hz,1H),7.00(d,J=8.3Hz,1H),6.84(d,J=9.0Hz,1H),3.02(s,6H),1.43(s,9H),13C NMR(125MHz,DMSO-d6)δ157.07,
156.60,156.58,155.74,154.41,150.27,150.18,141.81,141.16,140.43,140.28,139.85,136.89,135.94,132.38,127.51,112.95,107.44,79.47,55.39,45.51,38.57,28.55.HRMS(ESI)m/z calcd for[C27H33FN10O2+H]+:549.2845;found:549.2851[M+H]+.
叔丁基-4-(6-((2-((2-(二甲基氨基)-1H-苯并[d]咪唑-6-基)氨基)-5-氟嘧啶-4-基)氨基)吡啶-2-基)哌嗪-1-羧酸酯(化合物23h)
使用上述实施例10的方法,以化合物22h为原料,制备得到化合物23h,收率45%,灰白色固体。1H NMR(400MHz,DMSO-d6)δ9.30(s,1H),9.03(s,1H),8.26–7.99(m,3H),7.64(s,1H),7.35(dd,J=9.0,2.5Hz,1H),7.15(d,J=8.3Hz,1H),7.07(d,J=8.4Hz,1H),3.49(t,4H),3.10(t,4H),3.06(s,6H),1.43(s,9H).13C NMR(101MHz,DMSO-d6)δ156.76,156.52,149.34,149.23,145.16,143.69,141.64,141.42,141.23,139.19,136.46,134.10,125.96,116.05,113.38,111.56,104.59,79.51,52.45,49.08,38.60,28.52.HRMS(ESI)m/z calcdfor[C27H33FN10O2+H]+:549.2845;found:549.2849[M+H]+.
N6-(4-((4-(二甲基氨基)苯基)氨基)-5-氟嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物23i)
使用上述实施例10的方法,以化合物22i为原料,制备得到化合物23i,收率55%,白色固体。1H NMR(500MHz,DMSO-d6)δ9.02(s,1H),8.83(s,1H),7.98(d,J=3.2Hz,1H),7.64(s,1H),7.62(d,J=3.5Hz,2H),7.19(d,J=8.4Hz,1H),7.04(d,J=8.3Hz,1H),6.71(d,J=8.5Hz,2H),3.04(s,6H),2.86(s,6H).13C NMR(125MHz,DMSO-d6)δ157.20,156.79,150.28,150.20,147.40,141.78,140.05,139.90,139.83,134.12,129.14,123.14,113.07,111.32,104.43,40.99,38.56.HRMS(ESI)m/z calcd for[C21H23FN8+H]+:407.2102;found:407.2113[M+H]+.
实施例11:N6-(5-氟-4-((4-(哌嗪-1-基)苯基)氨基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物24a)
将23f(8.2g,15mmol)加入45mL的DCM/TAF=2/1中于100mL的茄形瓶中,室温搅拌4h。,旋干反应液,加三乙胺和甲醇反复旋干几次,得黑灰色油状物。用二氯甲烷和水萃取,水层用再用二氯甲烷洗涤5次直至水层在254nm无荧光,合并有机层,旋干,得黑灰色油状物,用硅胶柱层析进一步分离纯化(DCM:MeOH:Et3N=40:1:1)得白色固体3.50g,收率52%。1H NMR(500MHz,DMSO-d6)δ10.95(s,1H),9.04(s,1H),8.80(s,1H),7.97(d,J=3.3Hz,1H),7.64(d,J=8.5Hz,2H),7.56(s,1H),7.11(d,J=8.0Hz,1H),7.00(d,J=8.2Hz,1H),6.87(d,J=8.5Hz,2H),4.34(s,1H),3.03(s,6H),3.02–2.97(m,4H),2.86(m,4H).13C NMR(125MHz,DMSO-d6)δ157.40,156.82,156.80,150.10,150.01,148.05,141.68,140.35,140.19,139.73,133.88,131.43,122.63,115.94,113.41,50.25,45.98,38.55.HRMS(ESI)m/z calcd for[C23H26FN9+H]+:448.2368found:448.2372[M+H]+。
N6-(5-氟-4-((6-(哌嗪-1-基)吡啶-3-基)氨基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物24b)
使用上述实施例11的方法,以化合物23g为原料,制备得到化合物24b,收率47%,灰白色固体。1H NMR(500MHz,DMSO-d6)δ11.03(d,J=44.5Hz,1H),9.10(s,1H),8.82(d,J=30.5Hz,1H),8.47(d,J=16.6Hz,1H),7.97(t,J=11.2Hz,2H),7.55(d,J=34.2Hz,1H),7.12(s,1H),7.01(s,1H),6.77(s,1H),3.38–3.31(m,4H),3.02(s,6H),2.89–2.64(m,4H).(互变异构).13C NMR(125MHz,DMSO-d6)δ162.74,156.59,150.28,141.81,141.34,140.31,134.65,132.47,126.83,114.46,113.54,108.16,107.59,106.86,101.55,46.85,45.93,38.55.HRMS(ESI)m/z calcd for[C22H25FN10+H]+:449.2320;found:449.2323[M+H]+.
N6-(5-氟-4-((5-(哌嗪-1-基)吡啶-2-基)氨基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物24c)
使用上述实施例11的方法,以化合物23h为原料,制备得到化合物24c,收率49%,灰白色固体。1H NMR(400MHz,DMSO-d6)δ9.27(s,1H),8.99(s,1H),8.06(dd,J=13.3,6.3Hz,3H),7.60(s,1H),7.30(d,J=8.3Hz,1H),7.10(d,J=8.2Hz,1H),7.05(d,J=8.3Hz,1H),3.59(m,4H),3.36(s,1H),3.04(m,10H).13C NMR(101MHz,DMSO-d6)δ157.50,156.79,149.33,149.23,144.56,144.37,141.58,141.40,141.32,141.22,139.13,135.66,133.67,125.17,116.16,113.23,49.78,45.74,38.54.HRMS(ESI)m/z calcd for[C22H25FN10+H]+:449.2320;found:449.2321[M+H]+.
实施例12:N6-(5-氟-4-((4-(4-甲基哌嗪-1-基)苯基)氨基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物25a)
将装有10mL的ACN的25mL的茄形瓶放于-10℃冷肼中,将24a(0.45g,1mmol)和三乙胺(0.15g,1.5mmol)加入茄形瓶中,将碘甲烷(0.17g,1.2mmol)溶于2mLACN降温到-10℃,缓慢将其滴加到茄形瓶中,-10℃搅拌10min。用二氯甲烷和水萃取反应液,水层用再用二氯甲烷洗涤3次直至水层在254nm无荧光,合并有机层,旋干,得无色油状物,用硅胶柱层析进一步分离纯化(DCM:MeOH:Et3N=80:1:1)得白色固体0.20g,收率44%。1H NMR(500MHz,DMSO-d6)δ9.21(s,1H),9.18(s,1H),8.04(d,J=3.5Hz,1H),7.76(s,1H),7.68(d,J=8.7Hz,2H),7.44(d,J=8.4Hz,1H),7.19(d,J=8.6Hz,1H),6.97(d,J=8.8Hz,2H),3.41(s,4H),3.25(s,4H),3.19(s,6H),2.75(s,3H).13C NMR(125MHz,DMSO-d6)δ152.45,150.29,146.31,142.05,140.15,136.73,132.48,132.15,123.07,116.67,114.80,111.20,102.78,52.82,46.67,42.75,39.15.HRMS(ESI)m/z calcd for[C24H28FN9+H]+:462.2524found:462.2535[M+H]+.
实施例13:1-(4-(4-((2-((2-二甲基氨基)-1H-苯并[d]咪唑-6-基)氨基)-5-氟嘧啶-4-基)氨基)苯基)哌嗪-1-基)乙酮(化合物25b)
将24a(0.45g,1mmol),三乙胺(0.15g,1.5mmol)和乙酸酐(0.18g,1.5mmol)加入装有10mLACN的茄形瓶,室温搅拌2h。用二氯甲烷和水萃取反应液,水层用再用二氯甲烷洗涤3次直至水层在254nm无荧光,合并有机层,旋干,得无色油状物,用硅胶柱层析进一步分离纯化(DCM:MeOH:Et3N=80:1:1)得白色固体0.35g,收率71%。1H NMR(500MHz,DMSO-d6)δ11.33(s,1H),9.09(s,1H),8.87(s,1H),7.99(d,J=3.5Hz,1H),7.68(d,J=8.7Hz,2H),7.60(s,1H),7.16(d,J=8.2Hz,1H),7.03(d,J=8.4Hz,1H),6.92(d,J=8.8Hz,2H),3.58(m,4H),3.11–3.00(m,10H),2.05(s,3H).13C NMR(125MHz,DMSO-d6)δ168.69,156.66,150.08,150.00,147.20,141.72,140.38,140.25,139.77,134.32,131.99,122.61,116.71,113.26,49.44,46.01,38.61,21.67.HRMS(ESI)m/z calcd for[C25H28FN9O+H]+:490.2474found:490.2470[M+H]+.
实施例14:N6-(5-氟-4-((4-(4-异丙基哌嗪-1-基)苯基)氨基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物25c)
将24a(0.45g,1mmol),碳酸钾(0.41g,3mmol)和2-碘丙烷(0.51g,3mmol)加入装有10mLACN的茄形瓶,65℃搅拌16h。用二氯甲烷和水萃取反应液,水层用再用二氯甲烷洗涤3次直至水层在254nm无荧光,合并有机层,旋干,得无色油状物,用硅胶柱层析进一步分离纯化(DCM:MeOH:Et3N=80:1:1)得白色固体0.26g,收率53%。1H NMR(500MHz,DMSO-d6)δ9.05(s,1H),8.83(s,1H),7.98(s,1H),7.65(d,J=7.4Hz,2H),7.58(s,1H),7.14(d,J=7.2Hz,1H),7.02(d,J=7.6Hz,1H),6.88(d,J=7.3Hz,2H),3.10(s,4H),3.04(s,6H),2.76(s,1H),2.65(s,4H),1.04(s,6H).13C NMR(125MHz,DMSO-d6)δ157.08,156.73,150.10,150.02,147.41,141.71,140.35,140.31,140.18,139.75,134.11,131.47,122.66,116.05,113.10,54.39,49.34,48.54,38.57,18.53.HRMS(ESI)m/z calcd for[C26H32FN9+H]+:490.2837found:490.2841[M+H]+.
2-(4-(4-((2-((2-(二甲基氨基)-1H-苯并[d]咪唑-6-基)氨基)-5-氟嘧啶-4-基)氨基)苯基)哌嗪-1-基)乙-1-醇(化合物25d)
使用上述实施例13的方法,以化合物24a,2-溴乙醇为原料,制备得到化合物25d,收率70%,灰白色固体。1H NMR(500MHz,DMSO-d6)δ9.07(s,1H),8.84(s,1H),7.98(d,J=
3.7Hz,1H),7.65(d,J=8.9Hz,2H),7.58(s,1H),7.13(d,J=9.9Hz,1H),7.02(d,J=8.4Hz,1H),6.88(d,J=9.0Hz,2H),4.51(s,1H),3.56(t,J=6.2Hz,2H),3.14–3.05(m,4H),3.03(s,6H),2.59(s,4H),2.47(t,J=6.1Hz,2H).13C NMR(125MHz,DMSO-d6)δ156.98,156.72,156.57,150.10,147.38,141.71,140.33,140.17,139.79,134.26,131.48,122.71,116.05,113.28,111.42,104.52,60.48,58.70,53.47,48.95,38.62.HRMS(ESI)m/z calcdfor[C25H30FN9O+H]+:492.2630found:492.2636[M+H]+.
N6-(4-((4-(4-(乙基磺酰基)哌嗪-1-基)苯基)氨基)-5-氟嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物25e)
使用上述实施例13的方法,以化合物24a,乙烷磺酰氯为原料,制备得到化合物25e,收率68%,灰白色固体。1H NMR(500MHz,DMSO-d6)δ11.13(s,1H),9.08(s,1H),8.82(s,1H),7.99(d,J=3.7Hz,1H),7.69(d,J=8.9Hz,2H),7.57(s,1H),7.13(d,J=7.7Hz,1H),7.02(d,J=8.4Hz,1H),6.92(d,J=8.9Hz,2H),3.35–3.31(m,4H),3.22–3.14(m,4H),3.14–3.08(m,2H),3.04(s,6H),1.25(t,J=7.3Hz,3H).13C NMR(125MHz,DMSO-d6)δ157.10,156.74,156.69,150.02,149.63,146.87,146.54,141.78,140.37,140.17,139.41,133.82,132.44,132.32,132.25,122.58,116.93,112.77,49.62,45.67,42.90,38.56,7.95.HRMS(ESI)m/z calcd for[C25H30FN9O2S+H]+:540.2300found:540.2310[M+H]+.
N6-(5-氟-4-((4-(4-异戊基哌嗪-1-基)苯基)氨基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物25f)
将N6-(5-氟-4-((4-(哌嗪-1-基)苯基)氨基)嘧啶-2-基)-N 2,N 2-二甲基-1H-苯并[d]咪唑-2,6-二胺(0.45g,1mmol)和乙酸(0.06g,1mmol)加入装有10mL DCE的茄形瓶,60℃搅拌20min。再将三甲基乙醛(0.26g,3mmol)和三乙酸乙酯硼氢化钠(0.64g,3mmol)加入反应液中,60℃搅拌16h。用二氯甲烷和水萃取反应液,水层用再用二氯甲烷洗涤3次直至水层在254nm无荧光,合并有机层,旋干,得无色油状物,用硅胶柱层析进一步分离纯化(DCM:MeOH:Et3N=80:1:1)得白色固体0.316g,收率61%。1H NMR(500MHz,DMSO-d6)δ11.01(s,1H),9.04(s,1H),8.81(s,1H),7.97(d,J=3.3Hz,1H),7.65(d,J=8.4Hz,2H),7.57(s,1H),7.12(d,J=8.3Hz,1H),7.01(d,J=8.3Hz,1H),6.87(d,J=8.5Hz,2H),3.08(m,4H),3.03(s,6H),2.51(m,4H),2.34(t,J=7.4Hz,2H),1.61(m,1H),1.36(m,2H),0.90(d,J=6.6Hz,6H).13C NMR(125MHz,DMSO-d6)δ157.23,156.78,156.76,150.10,150.01,147.46,141.69,140.33,140.19,139.74,134.05,134.01,131.42,122.63,116.00,113.26,56.47,53.31,49.22,38.56,35.76,26.31,23.09.HRMS(ESI)m/z calcd for[C28H36FN9+H]+:518.3150found:518.3155[M+H]+.
N6-(4-((4-(4-苄基哌嗪-1-基)苯基)氨基)-5-氟嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物25g)
使用上述实施例12的方法,以化合物24a,溴苄为原料,制备得到化合物25g,收率70%,白色固体。1H NMR(500MHz,DMSO-d6)δ11.12(s,1H),9.07(s,1H),8.85(s,1H),7.98(d,J=3.4Hz,1H),7.65(d,J=8.6Hz,2H),7.58(s,1H),7.30(m,5H),7.13(d,J=8.2Hz,1H),7.01(d,J=8.3Hz,1H),6.87(d,J=8.7Hz,2H),3.08(m,4H),3.52(s,2H),3.01(s,6H),2.51(m,4H).13C NMR(125MHz,DMSO-d6)δ157.14,156.82,150.08,149.99,147.45,141.68,140.31,140.18,139.73,138.54,133.97,131.45,129.39,128.67,127.45,122.62,116.07,113.13,113.07,62.53,53.05,49.28,38.54.HRMS(ESI)m/z calcd for[C30H32FN9+H]+:538.2837found:538.2842[M+H]+.
1-(4-(4-((2-((2-(二甲基氨基)-1H-苯并[d]咪唑-6-基)氨基)-5-氟嘧啶-4-基)氨基)苯基)哌嗪-1-基)-3,3-二甲基丙-1酮(化合物25h)
使用上述实施例12的方法,以化合物24a,3,3-二甲基丁酰氯为原料,制备得到化合物25h,收率73%,白色固体。1H NMR(400MHz,DMSO-d6)δ9.12(s,1H),8.93(s,1H),8.00(d,J=3.7Hz,1H),7.69(t,J=8.8Hz,2H),7.64(s,1H),7.21(dd,J=8.5,1.4Hz,1H),7.07(d,J=8.4Hz,1H),6.92(d,J=9.0Hz,2H),3.67(t,J=16.6Hz,4H),3.05(d,J=10.6Hz,10H),2.28(s,2H),1.01(s,9H).13C NMR(101MHz,DMSO-d6)δ169.86,156.60,156.11,150.10,149.98,147.21,141.99,140.35,139.54,134.66,131.96,122.62,116.66,113.47,111.31,104.18,49.58,44.09,38.66,31.49,30.25.HRMS(ESI)m/z calcd for[C29H36FN9O+H]+:546.3100found:546.3106[M+H]+.
N-(叔丁基)-4-(4-((2-((2-(二甲基氨基)-1H-苯并[d]咪唑-6-基)氨基)-5-氟嘧啶-4-基)氨基)苯基)哌嗪-1-甲酰胺(化合物25i)
使用上述实施例12的方法,以化合物24a,叔丁基异氰酸酯为原料,制备得到化合物25i,收率68%,白色固体。1H NMR(500MHz,DMSO-d6)δ11.09(s,1H),9.08(s,1H),8.84(s,1H),7.99(s,1H),7.68(d,J=8.1Hz,2H),7.58(s,1H),7.13(d,J=6.7Hz,1H),7.02(d,J=7.6Hz,1H),6.91(d,J=8.1Hz,2H),5.92(s,1H),3.42(m,4H),3.04(m,10H),1.28(s,9H).13CNMR(125MHz,DMSO-d6)δ157.54,157.40,156.81,150.13,150.05,147.44,141.73,140.39,140.23,139.78,133.89,131.87,122.65,116.54,113.08,50.44,49.52,44.14,38.57,29.70.HRMS(ESI)m/z calcd for[C28H35FN10O+H]+:547.3052found:547.3060[M+H]+.
N6-(2-氯-5-氟嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物26)
使用上述实施例9的方法,以化合物12为原料,制备得到化合物26,收率88%,白色固体。1H NMR(500MHz,DMSO-d6)δ13.27(s,1H),10.13(s,1H),8.31(s,1H),7.85(s,1H),7.50(d,J=8.5Hz,1H),7.37(d,J=8.5Hz,1H),3.24(s,6H).HRMS(ESI)m/z calcd for[C13H12ClFN6+H]+:307.0869;found:307.0875[M+H]+.
叔丁基-6-((叔丁氧基碳酸酯)(2-氯-5-氟嘧啶-4-基)氨基)-2-(二甲基氨基)-1H-苯并[d]咪唑-1-羧酸酯(化合物27)
将N6-(2-氯-5-氟嘧啶-4-基)-N 2,N 2-二甲基-1H-苯并[d]咪唑-2,6-二胺(3.06g,10mmol)加入100mL的DCM中于250mL的茄形瓶中,加入(Boc)2O(21.81g,100mmol)、三乙胺(5.05g,50mmol)和DMAP(0.49g,4mmol)室温反应24h。,旋干反应液,得橙红色油状物。用二氯甲烷和水萃取,有机层用饱和柠檬酸的水溶液洗涤3次,再用饱和碳酸氢钠水溶液洗涤1次,最后用饱和食盐水洗涤1次。无水Na2SO4干燥有机层并放置4h。抽滤,旋干有机溶剂,得橙红色油状物,放置于油泵中抽干2h,得橙红色固体4.72g,收率93%。1H NMR(500MHz,DMSO-d6)δ8.96(s,1H),7.53(s,1H),7.33(d,J=8.3Hz,1H),7.09(d,J=8.3Hz,1H),2.99(s,6H),1.58(s,9H),1.42(s,9H)。HRMS(ESI)m/z calcd for[C23H28ClFN6O4+H]+:507.1917;found:507.1923[M+H]+.
叔丁基-6-((叔丁氧基碳酸酯)(5-氟-2-((4-(吡咯-1-基)苯基)氨基)嘧啶-4-基)氨基)-2-(二甲基氨基)-1H-苯并[d]咪唑-1-羧酸酯(化合物28a)
将6-((叔丁氧基羰基)(2-氯-5-氟嘧啶-4-基)氨基)-2-(二甲基氨基)-1H-苯并[d]咪唑-1-羧酸丁酯(2.53g,5mmol),4-(吡咯烷-1-基)苯胺(0.81g,5mmol),Pd2(dba)3(0.18g,0.02mmol),Xanphos(0.46g,0.08mmol),碳酸铯(4.89g,15mmol)加入120mL耐压瓶中,加入50mL二氧六环,加入搅拌子,用氮气置换瓶中空气,封好口后超声使原料尽可能溶解于溶剂中。放入120℃油浴中反应12h。之后放于室温冷却,冷却到室温后,旋干反应液,用二氯甲烷/水进行萃取,再用二氯甲烷对水层洗涤2次,无水Na2SO4干燥有机层并放置4h。抽滤,旋干有机溶剂,得黑色油状物,用硅胶柱层析对其分离纯化(DCM:MeOH:Et3N=200:1:1),得到黑色油状物2.34g,收率74%。结构未确证直接投下一步。28b-28f采用和28a相同的方法制备,同样未经结构确证直接投下一步。
N6-(5-氟-2-((4-(吡咯-1-基)苯基)氨基)嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物29a)
使用上述实施例11的方法,以化合物28a为原料,制备得到化合物29a,收率50%,灰白固体。1H NMR(500MHz,DMSO-d6)δ11.19(d,1H),9.01(d,,1H),8.67(s,1H),7.93(d,J=3.1Hz,1H),7.47(m 3H),7.25(m 1H),7.09(m 1H),6.40(m,2H),3.15(m,4H),3.05(s,6H),1.93(m,4H).13C NMR(125MHz,DMSO-d6)δ157.56,156.61,150.63,150.53,144.43,143.62,141.60,141.10,140.22,139.66,134.69,132.46,131.50,130.57,130.49,121.26,121.16,114.38,113.97,111.95,109.99,108.20,104.60,48.08,38.52,25.32.HRMS(ESI)m/zcalcd for[C23H25FN8+H]+:433.2259;found:443.2258[M+H]+.
N6-(5-氟-2-((4-(哌嗪-1-基)苯基)氨基)嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物29b)
使用上述实施例11的方法,以化合物28b为原料,制备得到化合物29b,收率45%,灰白固体。1H NMR(500MHz,DMSO-d6)δ11.19(s,1H),9.08(s,1H),8.84(s,1H),7.97(d,J=3.8Hz,1H),7.50(m,3H),7.21(s,1H),7.12(s,1H),6.74(s,2H),3.33(s,1H),3.06(s,6H),2.96–2.86(m,4H),2.85–2.71(m,4H).13C NMR(125MHz,DMSO-d6)δ157.76,156.37,150.76,150.68,146.73,141.75,140.35,140.34,140.21,140.19,139.80,133.81,120.17,116.31,114.35,50.92,46.19,38.51.HRMS(ESI)m/z calcd for[C23H26FN9+H]+:448.2368found:448.2370[M+H]+.
N6-(5-氟-2-((6-(哌嗪-1-基)吡啶-3-基)氨基)嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物29c)
使用上述实施例11的方法,以化合物28c为原料,制备得到化合物29c,收率65%,浅紫色固体。1H NMR(500MHz,DMSO-d6)δ11.19(s,1H),9.07(s,1H),8.82(s,1H),8.27(d,J=2.0Hz,1H),7.96(d,J=3.7Hz,1H),7.94–7.85(m,1H),7.47(s,1H),7.23(d,J=7.8Hz,1H),7.10(d,J=8.3Hz,1H),6.65(d,J=9.1Hz,1H),3.34–3.22(m,4H),3.05(s,6H),2.95–2.64(m,4H).13C NMR(125MHz,DMSO-d6)δ157.77,156.53,155.47,150.90,150.81,142.05,140.18,140.09,140.03,139.34,131.39,130.37,129.43,115.27,106.99,46.82,45.68,38.53.HRMS(ESI)m/z calcd for[C22H25FN10+H]+:449.2320found:449.2321[M+H]+.
N6-(2-((4-(二甲基氨基)苯基)氨基)-5-氟嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物29d)
使用上述实施例11的方法,以化合物28d为原料,制备得到化合物29d,收率65%,浅紫色固体。1H NMR(500MHz,DMSO-d6)δ11.37(s,1H),9.04(s,1H),8.73(s,1H),7.95(d,1H),7.51(s,1H),7.46(d,J=8.0Hz,2H),7.26(d,J=8.2Hz,1H),7.11(d,J=8.3Hz,1H),6.61(d,J=8.1Hz,2H),3.06(s,6H),2.80(s,6H).13C NMR(125MHz,DMSO-d6)δ157.37,156.53,150.67,150.59,146.15,141.69,140.35,140.19,139.74,131.81,131.67,120.76,115.36,113.48,111.16,107.34,41.28,38.58.HRMS(ESI)m/z calcd for[C20H22FN9+H]+:449.2320found:449.2319[M+H]+.
N6-(5-氟-2-((5-(哌嗪-1-基)吡啶-2-基)氨基)嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物29e)
使用上述实施例11的方法,以化合物28e为原料,制备得到化合物29e,收率68%,浅紫色固体。1H NMR(500MHz,DMSO-d6)δ11.37(s,1H),9.04(s,1H),8.73(s,1H),7.95(d,1H),7.51(s,1H),7.46(d,J=8.0Hz,2H),7.26(d,J=8.2Hz,1H),7.11(d,J=8.3Hz,1H),6.61(d,J=8.1Hz,2H),3.06(s,6H),2.80(s,6H).13C NMR(125MHz,DMSO-d6)δ157.37,156.53,150.67,150.59,146.15,141.69,140.35,140.19,139.74,131.81,131.67,120.76,115.36,113.48,111.16,107.34,41.28,38.58.HRMS(ESI)m/z calcd for[C20H22FN9+H]+:449.2320found:449.2319[M+H]+.
N6,N6-(5-氟嘧啶-2,4-二基)双(N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺)(化合物29h)
使用上述实施例11的方法,以化合物28f为原料,制备得到化合物29h,收率50%,白色固体。1H NMR(500MHz,DMSO-d6)δ8.11(d,J=4.1Hz,1H),7.69(s,1H),7.66(s,1H),7.58(d,J=8.2Hz,1H),7.34(m,2H),7.27(d,J=8.6Hz,1H),3.18(s,6H),3.16(s,6H).13CNMR(125MHz,DMSO-d6)δ152.64,152.55,151.81,151.53,151.42,140.72,138.74,133.43,132.38,130.94,130.77,128.38,127.52,119.24,117.67,111.44,111.20,107.04,105.32,39.50,39.48.HRMS(ESI)m/z calcd for[C22H23FN10+H]+:447.2164found:447.2169[M+H]+.
1-(4-(4-((4-((2-(二甲基氨基)-1H-苯并[d]咪唑-6-基)氨基)-5-氟嘧啶-2-基)氨基)苯基)哌嗪-1-基)丙-1-酮(化合物29f)
使用上述实施例13的方法,以化合物29b为原料,制备得到化合物29f,收率60%,白色固体。1H NMR(400MHz,DMSO-d6)δ9.19(s,1H),8.92(s,1H),8.00(d,J=3.7Hz,1H),7.58(s,1H),7.55(d,J=8.8Hz,2H),7.35(d,J=8.3Hz,1H),7.18(d,J=8.4Hz,1H),6.80(d,J=8.9Hz,2H),3.77–3.33(m,4H),3.10(s,6H),3.06–2.83(m,4H),2.04(s,3H).13C NMR(101MHz,DMSO-d6)δ168.66,156.28,150.64,150.53,145.77,142.05,140.50,140.32,139.61,134.48,132.17,120.17,117.08,115.88,111.24,107.13,50.35,49.92,38.69,21.66.HRMS(ESI)m/z calcd for[C25H28FN9O+H]+:490.2474found:490.2475[M+H]+.
N6-(5-氟-4-((4-(4-异戊基哌嗪-1-基)苯基)氨基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺(化合物29g)
使用上述实施例13的方法,以化合物29b为原料,制备得到化合物29g,收率65%,白色固体。1H NMR(500MHz,DMSO-d6)δ11.51(s,1H),9.19(s,1H),8.92(s,1H),8.00(d,J=3.0Hz,1H),7.58(s,1H),7.55(d,J=8.3Hz,2H),7.37(d,J=8.3Hz,1H),7.18(d,J=8.4Hz,1H),6.82(d,J=8.4Hz,2H),3.18(d,J=68.6Hz,14H),2.89(s,2H),1.66–1.47(m,3H),0.91(d,J=5.8Hz,6H).13C NMR(125MHz,DMSO-d6)δ156.28,155.93,150.61,150.52,144.91,141.83,140.49,140.34,139.88,134.61,132.41,120.26,116.81,116.05,111.24,106.91,55.09,51.77,47.54,38.79,33.00,26.26,22.77.HRMS(ESI)m/z calcd for[C28H36FN9+H]+:518.3150found:518.3152[M+H]+.
实施例15:对所合成的化合物进行HIPK2的抑制活性实验、对所合成的化合物进行大鼠肾成纤维细胞(NRK-49F)的增殖抑制实验
一、对所合成的化合物进行HIPK2的抑制活性实验
1.实验材料
HIPK2激酶(Carna);MBP、ATP(Promega)、ADP-GloTM检测试剂盒、Cytation 5。
2.实验方法
(1)在384孔板中加入1μL化合物溶液(或5%DMSO),2μL HIPK2溶液,2μL ATP和底物的混合溶液,室温培育60min;
(2)加入5μLADP-GloTM试剂,室温培育40min;
(3)加入10μL激酶消除试剂,室温培育30min;
(4)记录荧光强度。
二、对所合成的化合物进行大鼠肾成纤维细胞(NRK-49F)的增殖抑制实验
1.实验材料
(1)细胞株:大鼠肾成纤维细胞(NRK-49F)
(2)试剂与仪器:96孔板(Corning);胎牛血清(Gibco),F12培养基,DMEM培养基(BI);生物安全柜,二氧化碳培养箱(ESCO);Cytation 5多功能成像仪(Bio-Tek)。
2.实验方法
(1)细胞培养:NRK-49F细胞采用常规培养。实验时均用处于对数生长期且活细胞比例高于90%的细胞进行实验。
(2)细胞生长检测:消化细胞,将细胞稀释成浓度为3-5×104个/mL的细胞悬液,向96孔板中间60孔中每孔加入100μL细胞悬液(每孔3-5×103个细胞),四周36孔中每孔加入100μL PBS;将96孔板置于37℃,5% CO2的培养箱中培养至贴壁(进入对数生长期);吸取中间60孔中培养基后,向每个孔中加入100μL含不同浓度化合物的培养基,每组3复孔;将96孔板置于培养箱中培养48h;弃去含化合物的培养基以及PBS,96孔板每孔加入100μL含10%CCK-8的基础培基,将96孔板在培养箱内孵育1-4h后,用酶标仪测定在450nm处的OD值。
3.实验结果
表1目标化合物对HIPK2激酶抑制活性、NRK-49F细胞增殖抑制活性
说明:a化合物最大浓度为10μM,括号内数据为最大浓度下的抑制率,例如>10(2.7%)即在浓度为10μM下的抑制率;b化合物最大浓度为100μM,括号内数据为最大浓度下的抑制率;c专利CN106565673披露的活性Wnt抑制剂d专利CN105017159披露的5-氟-2,4-二取代嘧啶衍生物。
以上数据结果显示,多数目标化合物化合物的HIPK2的抑制活性实验结果与肾成纤维细胞(NRK-49F)的增殖抑制实验结果趋势一致,且活性强于已上市抗纤维化药物吡非尼酮,并优于对比文献的化合物,具有明显的活性优势。
实施例16:目标化合物对纤维化的影响
1.实验材料
(1)细胞株:大鼠肾成纤维细胞(NRK-49F)
(2)抗体:P65、p-P65、α-SMA、Fn1、Collagen1、GAPDH均购自CST公司。
(3)药品及试剂:超敏ECL化学发光试剂购自Abbkine公司;羊抗兔二抗,显影液、定影液,RIPA裂解液,BSA,BCA蛋白浓度检测试剂盒,预染蛋白marker,均购自南京恩晶生物科技有限公司。
(4)仪器及耗材:6孔细胞培养板购自corning公司;超净工作台(ESCO);二氧化碳培养箱(ESCO);荧光倒置生物显微镜(optec);台式高速离心机(SCILOGEX);微型垂直电泳槽(Bio-RAD);转移电泳槽(Bio-RAD);电泳仪(君意有限公司);脱色摇床(华利达有限公司);Cytation 5酶标仪(Bio-tek公司)。
2.实验方法
(1)蛋白样本制备
取对数生长期NRK-49F的细胞进行实验。细胞经消化、计数、稀释成2×105个/mL的细胞悬液,以每孔2mL接种于6孔板中,置于37℃,5% CO2培养箱中培养24小时;更换新鲜培养基,同时设立空白对照组和实验组(加TGF-β刺激),加入不同浓度的化合物7a,作用24h后,倒掉培养液,每个孔细胞加2mL 4℃预冷的PBS洗涤三次。之后培养皿置于冰上。加入100μL的RIPA裂解液(含磷酸酶抑制剂和PMSF)裂解30min,需要经常来回摇动以使细胞充分裂解。裂解完后,用刮棒将细胞快速刮到孔的一侧,然后用移液枪将孔中液体移至1.5mL离心管中(整个操作均需在冰上进行)。最后在4℃温度下12000rpm离心5min,将离心后的上清液转移到0.5mL的离心管中,用蛋白定量测定试剂盒测定上清液中蛋白的浓度,将上清液放于-20℃中保存,电泳上样前要将样品蛋白变性。
(2)SDS-PAGE电泳
将干净的玻璃板对齐后放入夹中,垂直卡在架子上准备灌胶。吸取5mL的分离胶沿玻璃缓慢灌入,胶面升到绿带中间线的高度时即可停止,然后胶上加一层无水乙醇进行液封。胶凝后就可倒去胶上层水并用吸水纸将水吸干。用浓缩胶将剩余空间灌满后将梳子插入浓缩胶中。浓缩胶凝固后,将梳子竖直向上轻轻将拔出。用水冲洗浓缩胶后,将其放入电泳槽中。上样30-50μg蛋白,在加入足够的电泳缓冲液后上样。先用70V电泳20min,等到蛋白聚集到分离胶界限的时候将电压换成130V,电泳至溴酚兰刚跑出时终止电泳,进行转膜。
(3)转膜
用撬胶板小心地将玻璃板撬开,小心地将胶平铺在三张滤纸上,去除气泡。将浸泡好了的PVDF膜贴在所需目标条带的地方,小心去除气泡后不能再移动。再叠放三张滤纸在PVDF膜上,注意胶两侧上下方的滤纸不能直接接触,以免形成短路损坏转膜设备。确认无误后,盖上海绵垫合上转膜板。按照PVDF膜在正极胶在负极的方式放置转模板,在转膜槽中加入转膜缓冲液,并将转膜槽置于冰水混合物中,80V条件下转膜45min。转膜完成后取出PVDF膜,用TBS浸润后放入封闭液中,4℃过夜封闭。封闭完后,将膜从封闭液中取出,在用滤纸吸除残留的封闭液后,将膜蛋白面朝下放于已经稀释到特定浓度的一抗溶液的液面上,掀动膜的四角以赶出残留气泡后;室温下孵育2h。一抗孵育完毕后将PVDF膜用TBST在水平摇床上10min/次清洗,重复3次。用和孵育一抗相同的方法给PVDF膜孵育二抗(1:5000稀释),室温条件下孵育1h。随后再次将PVDF膜用TBST在水平摇床上10min/次清洗,重复3次,之后进行化学发光显影。
(4)化学发光显影
将ECL发光液的A液和B液按1:1得比例混合,室温条件下静置1min。将PVDF膜蛋白质面向上贴在平板上。1min后涂上ECL发光液进行显影及定影。以GAPDH为内参,用AdobePhotoshop CS5软件分析目标条带的净光密度值。
(5)统计学处理
扫描仪扫描显影条带,所得结果用ImageJ软件扫描得其灰度值,用Graphpad软件作图。
3.实验结果
得到的结果如图2所示。其中(A)、(C)用Western blot检测经不同浓度的化合物7a处理后NRK-49F细胞α-SMA和Fn 1的表达;(B)、(D)对Western blot数据的定量分析。####表示与阴性对照组(0/-)相比p<0.0001,###表示与阴性对照组(0/-)相比p<0.001,***表示与阳性对照组(0/+)相比p<0.001,****表示与阳性对照组(0/+)相比p<0.0001。
4.实验结论
由图2可知,加入10ng/mL的TGF-β后,细胞内α-SMA、Fn1的水平明显上升;通过7a处理后,细胞内α-SMA、Fn1的水平明显下降。因此7a可以通过抑制HIPK2而抑制其下游纤维化信号通路相关分子的表达。
实施例17:化合物对炎症相关通路的影响
1.实验材料
抗体:P65、p-P65、GAPDH均购自CST公司。其他同实施例16。
2.实验方法(同实施例16)
3.实验结果
得到的结果如图3所示。其中(A)用Western blot检测经不同浓度的化合物7a处理后NRK-49F细胞P-P65和P65的表达;(B)、(C)对左中Western blot数据的定量分析。***表示与阳性对照组(0/+)相比p<0.001,****表示与阳性对照组(0/+)相比p<0.0001。
如图所示,给予不同浓度的7a治疗,低浓度时,P65有所上升;高浓度时,P65相较于低浓度时显著下降,与对照组相差不大。但P65的磷酸化水平有明显的下降。
4.实验结论
7a可以通过抑制HIPK2而抑制其下游炎症信号通路相关分子的表达。
实施例18:化合物对单侧输尿管结扎小鼠肾间质纤维化模型的影响
单侧输尿管结扎模型(UUO模型)是经典的肾间质纤维化模型,其模拟了从肾急性损伤,逐渐进展到肾间质纤维化整个动态过程。一般认为输尿管结扎后3天为损伤的急性期,主要以细胞水肿、死亡及炎性细胞浸润为主;第3-7天为亚急性期,主要以肾间质水肿、肾小管扩张、炎性细胞浸润为主,开始出现细胞外基质沉积;7天以后肾间质水肿、肾小管扩张逐渐消失,取而代之的是肾间质萎缩、间质细胞外基质沉积明显增加、纤维化恶化,进入慢性期。本研究目的:观察本发明的目标化合物(HIPK2-inhibitor)对UUO14天模型的疗效,以明确目标化合物对肾间质纤维化的治疗效果。
1.实验材料
1.1药品:目标化合物(HIPK2-inhibitor);性状:黄色固体。提供单位:中南大学药学院。双蒸水作为溶剂溶解目标化合物(调节pH=4.5左右)。
1.2实验动物:C57-BL6小鼠,雄性,体重22-25g,购于湖南斯莱克景达实验动物有限公司,实验动物生产许可证号:SCXK(湘)2015-0017。
2.实验方法
2.1试验设计
SPF级雄性小鼠分为假手术组(Sham)、单侧输尿管结扎组(UUO)、UUO+目标化合物(75mg/kg)组,麻醉后剃去背部毛发,络合碘消毒,除假手术组外所有小鼠取背部正中线左上方剪开皮肤小口,暴露出后侧腹膜,随后剪开腹膜,挤出左侧肾脏及输尿管,在输尿管近肾门处及输尿管下方予以3-0缝线结扎,于两处结扎处中间剪断输尿管后将肾脏推回腹腔,并缝合腹膜及背部皮肤。假手术组小鼠仅予以开腹和关腹处理。模型构建后第2天开始UUO+目标化合物(75mg/kg)组予以目标化合物以75mg/kg/6mL灌胃给药,1次/日,连续14天,术后第14天处死小鼠。
2.2检测指标
2.2.1样品配制及供试品分析:根据小鼠体重称取足够量的化合物7a,调节PH后使用双蒸水作为溶剂配制成相应浓度的药液。
2.2.2对肾脏组织病理学的影响:给药14天后将所有小鼠予以CO2麻醉安乐死,立即放血,取左侧肾脏一半置于福尔马林固定并进行脱水,石蜡包埋,切片,分别进行HE染色、masson染色,其中HE染色的组织切片采用肾脏损伤评分标准进行病理学评分,masson染色的组织切片采用肾脏纤维化评分标准进行病理学评分。具体评分标准和面积计算方法如下:
HE染色:将肾脏组织病变分类,分别为肾间质纤维化、肾间质炎症、肾小管空泡变性、肾小管萎缩、肾小管扩张、肾间质水肿、红细胞管型、蛋白管型。分别对上述各种类型病变进行评分,其中正常:记“0”分;轻度:记“1”分;中度:记“2”分;重度:记“3”分,并将每只动物得分相加,得总分。分别对上述各类型得分及总得分进行统计。
masson染色:按细胞外基质沉积的面积计算,0-25%、25-50%、50-75%、大于75%分别记1、2、3、4分。
2.3统计方法
统计所用软件为SPSS20.0。如果方差齐性,用单因素方差分析(One-Way ANOVA)进行统计分析。如果方差不齐,则用Kruskal-Wallis检验。如果Kruskal-Wallis检验有统计学意义(P<0.05),则用Dunnett’s Test(非参数方法)进行比较分析。统计结果以P<0.05表示有统计学意义,P<0.01表示所检验的差别有非常显著性意义。
3.实验结果
3.1.对肾脏HE染色病理评分的影响
如图4-6和图10所示,与假手术组(Sham)比较,UUO组小鼠14天的肾脏中炎性细胞浸润、肾小管萎缩、肾间质纤维化明显,HE染色病理评分均显著升高(P<0.05);与UUO组比较,化合物组(仅列出7a和25f的数据)肾脏炎性细胞浸润、肾小管萎缩、肾间质纤维化明显减少,而肾小管扩张病变明显,化合物组(仅列出7a和25f的数据)HE染色病理评分降低(P<0.05)。其他目标化合物组的也表现出明显的肾脏炎性细胞浸润、肾小管萎缩、肾间质纤维化明显减少。
3.2对肾脏masson染色病理评分的影响
如图7-9和图10所示,与假手术组(Sham)比较,UUO组小鼠14天的肾脏肾间质纤维化沉积明显,masson染色病理评分均显著升高(P<0.01);与UUO组比较,化合物组(仅列出7a和25f的数据)肾脏肾间质纤维化沉积明显减少,masson染色病理评分显著降低(P<0.05)。其他目标化合物组的也表现出明显的肾脏肾间质纤维化沉积明显减少,masson染色病理评分显著降低。
4.结论:
本发明的2,4-二取代-5-氟嘧啶衍生物可以减轻肾损伤和肾间质纤维化沉积。
Claims (14)
1.一种2,4-二取代-5-氟嘧啶类衍生物,其特征在于,其结构通式如式I所示:
其中,R1和R2分别独立选自:
R4选自:
X,Y分别独立选自氮原子或碳原子;Z选自氢原子,叔丁氧羰基,C1-C5烷基,C1-C5烷基酰基,C1-C3烷基羟基,C1-C3烷基磺酰基,C1-C3取代苯基,C1-C5烷基酰胺基。
2.根据权利要求1所述的2,4-二取代-5-氟嘧啶类衍生物,其特征在于,R1和R2任一为:R4为Z选自氢原子,C1-C5烷基,C1-C5烷基酰基,C1-C3烷基羟基,C1-C3烷基磺酰基,C1-C3取代苯基,C1-C5烷基酰胺基。
3.根据权利要求1所述的2,4-二取代-5-氟嘧啶类衍生物,其特征在于,R1和R2任一为:R4为Z为丁基,戊基,异丁基,异戊基,R1和R2另一为:时,X,Y不同时为碳原子。
4.一种2,4-二取代-5-氟嘧啶类衍生物,其特征在于,其结构通式如式II或式III所示:
其中,R3选自:
R4选自:
X,Y分别独立选自氮原子或碳原子;Z选自氢原子,叔丁氧羰基,C1-C5烷基,C1-C5烷基酰基,C1-C3烷基羟基,C1-C3烷基磺酰基,C1-C3取代苯基,C1-C5烷基酰胺基。
5.根据权利要求4所述的2,4-二取代-5-氟嘧啶类衍生物,其特征在于,在R3中,R4为时,Z不为叔丁氧羰基。
6.根据权利要求4所述的2,4-二取代-5-氟嘧啶类衍生物,其特征在于,式III中的R4为时,Z不为叔丁氧羰基、C4-C5烷基、C4-C5烷基酰基,C4-C5烷基酰胺基。
7.根据权利要求1-6任一项所述的2,4-二取代-5-氟嘧啶类衍生物,其特征在于,C1-C5烷基包括甲基,乙基,丙基,丁基,戊基,异丁基,异戊基,异丙基。
8.根据权利要求1-6任一项所述的2,4-二取代-5-氟嘧啶类衍生物,其特征在于,C1-C5烷基酰基包括甲酰基,乙酰基,丙酰基,丁酰基,戊酰基,3,3-二甲基-1-丁酰基,异戊酰基。
9.根据权利要求1-6任一项所述的2,4-二取代-5-氟嘧啶类衍生物,其特征在于,C1-C5烷基酰胺基包括甲酰胺基,乙酰胺基,丙酰胺基,丁酰胺基,戊酰胺基,N-叔丁基胺基甲酰基,异戊酰胺基。
10.根据权利要求1或4所述的2,4-二取代-5-氟嘧啶类衍生物,其特征在于,具体为以下化合物:
叔丁基-4-(4-((5-氟-2-((4-(甲氧甲酰基)苯基)氨基)吡啶-4-基)氨基)苯基)哌嗪-1-羧酸酯;
1-(5-氟-4-((4-(4-甲基哌嗪-1-基)苯基)氨基)嘧啶-2-基)-1H-苯并[d]咪唑-2-胺;1-(4-((4-(4-乙基哌嗪-1-基)苯基)氨基)-5-氟嘧啶-2-基)-1H-苯并[d]咪唑-2-胺;N2-(1H-苯并[d]咪唑-2-基)-N4-(4-(4-乙基哌嗪-1-基)苯基)-5-氟嘧啶-2,4-二胺;
1-(5-氟-4-((4-(哌嗪-1-基)苯基)氨基)嘧啶-2-基)-1H-苯并[d]咪唑-2-胺;
5-氟-N2-(异喹啉-3-基)-N4-(4-(哌嗪-1-基)苯基)嘧啶-2,4-二胺;
5-氟-N4-(4-哌嗪-1-基)苯基-N2-((四氢呋喃-2-基)甲基)嘧啶-2,4-二胺;
5-氟-N4-(4-(哌嗪-1-基)苯基-N2-(吡啶-2-基甲基)嘧啶-2,4-二胺;
甲基-4-(5-氟-4-((4-(哌嗪-1-基)苯基)氨基)嘧啶-2-基)氨基苯甲酸酯;
1-(5-氟-4-((4-(4-异戊基哌嗪-1-基)苯基)氨基)嘧啶-2-基)-1H-苯并[d]咪唑-2-胺;
5-氟-N4-(4-(4-异戊基哌嗪-1-基)苯基)-N2-((四氢呋喃-2-基)甲基)嘧啶-2,4-二胺;
5-氟-N4-(4-(4-异戊基哌嗪-1-基)苯基)-N2-(吡啶-2-基甲基)嘧啶-2,4-二胺;
1-(5-氟-4-(6-(哌嗪-1-基)吡啶-3-基)嘧啶-2-基)-1H-苯并[d]咪唑-2-胺;
N6-(5-氟-4-((4-吗啉苯基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
N6-(5-氟-4-((4-(吡咯-1-基)苯基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
N6-(4-((4-(二乙基胺基)苯基)胺基)-5-氟嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
N6-(4-((4-(二丙基胺基)苯基)胺基)-5-氟嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
N6-(5-氟-4-((4-(哌啶-1-基)苯基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
N6-(4-((4-(二甲基胺基)苯基)胺基)-5-氟嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
叔丁基-4-(5-((2-((2-(二甲基胺基)-1H-苯并[d]咪唑-6-基)胺基)-5-氟嘧啶-4-基)胺基)吡啶-2-基)哌嗪-1-羧酸酯;
叔丁基-4-(5-((2-((2-(二甲基胺基)-1H-苯并[d]咪唑-6-基)胺基)-5-氟嘧啶-4-基)胺基)吡啶-3-基)哌嗪-1-羧酸酯;
N6-(5-氟-4-((4-(哌嗪-1-基)苯基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
N6-(5-氟-4-((6-(哌嗪-1-基)吡啶-3-基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
N6-(5-氟-4-((5-(哌嗪-1-基)吡啶-2-基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
N6-(5-氟-4-((4-(4-甲基哌嗪-1-基)苯基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
1-(4-(4-((2-((2-(二甲基胺基)-1H-苯并[d]咪唑-6-基)胺基)-5-氟嘧啶-4-基)胺基)苯基)哌嗪-1-基)乙酮;
N6-(5-氟-4-((4-(4-异丙基哌嗪-1-基)苯基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
2-(4-(4-((2-((2-(二甲基胺基)-1H-苯并[d]咪唑-6-基)胺基)-5-氟嘧啶-4-基)胺基)苯基)哌嗪-1-基)乙醇;
N6-(4-((4-(4-(乙基磺酰基)哌嗪-1-基)苯基)胺基)-5-氟嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
N6-(5-氟-4-((4-(4-异戊基哌嗪-1-基)苯基)胺基)嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
N6-(4-((4-(4-苄基哌嗪-1-基)苯基)胺基)-5-氟嘧啶-2-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
1-(4-(4-((2-((2-(二甲基胺基)-1H-苯并[d]咪唑-6-基)胺基)-5-氟嘧啶-4-基)胺基)苯基)哌嗪-1-基)-3,3-二甲基丁-1-酮;
N-(叔丁基)-4-(4-((2-((2-(二甲基胺基)-1H-苯并[d]咪唑-6-基)胺基)-5-氟嘧啶-4-基)胺基)苯基)哌嗪-1-甲酰胺;
N6-(5-氟-2-((4-(吡咯-1-基)苯基)胺基)嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
N6-(5-氟-2-((4-(哌嗪-1-基)苯基)胺基)嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
N6-(5-氟-2-((6-(哌嗪-1-基)吡啶-3-基)胺基)嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
N6-(2-((4-(二甲基胺基)苯基)胺基)-5-氟嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
N6-(5-氟-2-((5-(哌嗪-1-基)吡啶-2-基)胺基)嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
1-(4-(4-((4-((2-(二甲基胺基)-1H-苯并[d]咪唑-6-基)胺基)-5-氟嘧啶-2-基)胺基)苯基)哌嗪-1-基)乙酮;
N6-(5-氟-2-((4-(4-异戊基哌嗪-1-基)苯基)胺基)嘧啶-4-基)-N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺;
N6,N6-(5-氟嘧啶-2,4-二基)双(N2,N2-二甲基-1H-苯并[d]咪唑-2,6-二胺)。
11.一种制备权利要求1-10任一项所述的2,4-二取代-5-氟嘧啶类衍生物的方法,其特征在于,包括以下步骤:
2,4-二氯-5-氟-嘧啶与胺类化合物反应得到化合物I或II,2,4-二氯-5-氟-嘧啶与硼酸酯反应生成的中间体继续与2-氨基苯并咪唑反应得到化合物III。
12.一种药物组合物,其特征在于,包含权利要求1-10任一项所述的2,4-二取代-5-氟嘧啶类衍生物或其药学上可用的盐以及药学上可接受的载体和辅料。
13.权利要求1-10任一项所述的2,4-二取代-5-氟嘧啶类衍生物及权利要求12所述的组合物在制备治疗纤维化的药物中的应用。
14.根据权利要求13所述应用,其特征在于,所述纤维化是指肾间质纤维化。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210487958 | 2022-05-06 | ||
CN2022104879582 | 2022-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116514779A true CN116514779A (zh) | 2023-08-01 |
Family
ID=87393494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310456800.3A Pending CN116514779A (zh) | 2022-05-06 | 2023-04-25 | 2,4-二取代-5-氟嘧啶衍生物及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116514779A (zh) |
WO (1) | WO2023213211A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023213211A1 (zh) * | 2022-05-06 | 2023-11-09 | 长沙晶易医药科技股份有限公司 | 2,4-二取代-5-氟嘧啶衍生物及其制备方法和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010529193A (ja) * | 2007-06-11 | 2010-08-26 | ミイカナ セラピューティクス インコーポレイテッド | 置換ピラゾール化合物 |
UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
CN105592850B (zh) * | 2013-08-06 | 2019-11-15 | H·李·莫菲特癌症中心研究所公司 | Ack1/tnk2酪氨酸激酶的抑制剂 |
CN114230524A (zh) * | 2021-12-28 | 2022-03-25 | 南通大学 | (5-氟-2-苯胺嘧啶-4-基)氨基-n-羟基苯甲酰胺衍生物及其制备方法与应用 |
CN116514779A (zh) * | 2022-05-06 | 2023-08-01 | 中南大学 | 2,4-二取代-5-氟嘧啶衍生物及其制备方法和应用 |
-
2023
- 2023-04-25 CN CN202310456800.3A patent/CN116514779A/zh active Pending
- 2023-04-25 WO PCT/CN2023/090579 patent/WO2023213211A1/zh active Search and Examination
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023213211A1 (zh) * | 2022-05-06 | 2023-11-09 | 长沙晶易医药科技股份有限公司 | 2,4-二取代-5-氟嘧啶衍生物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2023213211A9 (zh) | 2024-03-21 |
WO2023213211A1 (zh) | 2023-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vicini et al. | Synthesis and antiproliferative activity of benzo [d] isothiazole hydrazones | |
AU2014337291B2 (en) | Pyrimidine FGFR4 inhibitors | |
EP2991982B1 (en) | Novel compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | |
AU2020275818B2 (en) | Fluorine-containing compound and anti-cancer medical use thereof | |
Liu et al. | Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1, 2, 4-triazolone moiety as c-Met kinase inhibitors | |
EA016345B1 (ru) | Новые сульфонилпирролы в качестве ингибиторов гдац (гистондезацетилазы) | |
EP2698367A1 (en) | Benzimidazoles for the treatment of cancer | |
FR2857966A1 (fr) | Produits aryl-heteroaromatiques, compositions les contenant et utilisation | |
CN109310671A (zh) | 布鲁顿酪氨酸激酶抑制剂 | |
JP2021176847A (ja) | 置換5員および6員複素環式化合物、その調製方法、薬剤の組み合わせおよびその使用 | |
CN107151250B (zh) | 嘧啶类七元环化合物、其制备方法、药用组合物及其应用 | |
KR101373911B1 (ko) | Bcl 단백질과 결합 파트너의 상호작용을 억제하기 위한화합물 및 방법 | |
TW202135831A (zh) | 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途 | |
CN116514779A (zh) | 2,4-二取代-5-氟嘧啶衍生物及其制备方法和应用 | |
EP3456712B1 (en) | Novel 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof | |
JP4564713B2 (ja) | 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法 | |
AU2016218942A1 (en) | Inhibitors of necroptosis | |
EP3445170A1 (en) | Quinoline compounds as modulators of rage activity and uses thereof | |
KR20100132553A (ko) | 신규한 n-(2-아미노-페닐)-아크릴아미드 | |
EA010392B1 (ru) | Производные имидазолов, способ их получения и их применение в качестве лекарственного средства | |
JP2021509399A (ja) | インドールアミン−2,3−ジオキシゲナーゼ阻害剤およびその調製方法と使用 | |
CN109641909A (zh) | 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用 | |
CA2787860C (en) | Substituted 2-imidazolidones and analogs and their use against cancer | |
WO2017034377A1 (en) | Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) | |
KR20000029564A (ko) | 5HT2c길항제및D2길항제를함유하는약제학적조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20231018 Address after: Room 801, 8th Floor, Building A-3, Jinrui Lugu Science and Technology Park, No. 28 Lutian Road, Changsha High tech Development Zone, Changsha City, Hunan Province, 410221 Applicant after: Changsha Jingyi Pharmaceutical Technology Co.,Ltd. Address before: Yuelu District City, Hunan province 410083 Changsha Lushan Road No. 932 Applicant before: CENTRAL SOUTH University |